Breast Cancer, Version 3.2020

William J. Gradishar, MD^{1,*}; Benjamin O. Anderson, MD^{2,*}; Jame Abraham, MD³; Rebecca Aft, MD, PhD⁴; Doreen Agnese, MD⁵; Kimberly H. Allison, MD⁶; Sarah L. Blair, MD⁷; Harold J. Burstein, MD, PhD⁸; Chau Dang, MD⁹; Anthony D. Elias, MD¹⁰; Sharon H. Giordano, MD, MPH¹¹; Matthew P. Goetz, MD¹²; Lori J. Goldstein, MD¹³; Steven J. Isakoff, MD, PhD¹⁴; Jairam Krishnamurthy, MD¹⁵; Janice Lyons, MD³; P. Kelly Marcom, MD¹⁶; Jennifer Matro, MD¹⁷; Ingrid A. Mayer, MD¹⁸; Meena S. Moran, MD¹⁹; Joanne Mortimer, MD²⁰; Ruth M. O'Regan, MD²¹; Sameer A. Patel, MD¹³; Lori J. Pierce, MD²²; Hope S. Rugo, MD²³; Amy Sitapati, MD⁷; Karen Lisa Smith, MD, MPH²⁴; Mary Lou Smith, JD, MBA²⁵; Hatem Soliman, MD²⁶; Erica M. Stringer-Reasor, MD²⁷; Melinda L. Telli, MD⁶; John H. Ward, MD²⁸; Jessica S. Young, MD²⁹; Jennifer L. Burns³⁰; and Rashmi Kumar, PhD³⁰

ABSTRACT

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.

J Natl Compr Canc Netw 2020;18(4):452–478
doi: 10.6004/jnccn.2020.0016

NCCN CATEGORIES OF EVIDENCE AND CONSENSUS

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Clinical trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PLEASE NOTE

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network[®] (NCCN[®]) makes no representations or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

The complete NCCN Guidelines for Breast Cancer are not printed in this issue of JNCCN but can be accessed online at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Disclosures for the NCCN Breast Cancer Panel

At the beginning of each NCCN Guidelines Panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

Individual disclosures for the NCCN Breast Cancer Panel members can be found on page 478. (The most recent version of these guidelines and accompanying disclosures are available at NCCN.org.)

The complete and most recent version of these guidelines is available free of charge at NCCN.org.

¹Robert H. Lurie Comprehensive Cancer Center of Northwestern University; ²Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; ³Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; ⁴Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; ⁵The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; ⁶Stanford Cancer Institute; ⁷UC San Diego Moores Cancer Center; ⁸Dana-Farber/Brigham and Women's Cancer Center; ⁹Memorial Sloan Kettering Cancer Center; ¹⁰University of Colorado Cancer Center; ¹¹The University of Texas MD Anderson Cancer Center; ¹²Mayo Clinic Cancer Center; ¹³Fox Chase Cancer Center; ¹⁴Massachusetts General Hospital Cancer Center; ¹⁵Fred & Pamela Buffett Cancer Center; ¹⁶Duke Cancer Institute; ¹⁷Abramson Cancer Center at the University of Pennsylvania; ¹⁸Vanderbilt-Ingram Cancer Center; ¹⁹Yale Cancer Center/Smilow Cancer Hospital; ²⁰City of Hope National Medical Center; ²¹University of Wisconsin Carbone Cancer Center; ²²University of Michigan Rogel Cancer Center; ²³UCSF Helen Diller Family Comprehensive Cancer Center; ²⁴The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; ²⁵Research Advocacy Network; ²⁶Moffitt Cancer Center; ²⁷O'Neal Comprehensive Cancer Center at UAB; ²⁸Huntsman Cancer Institute at the University of Utah; ²⁹Roswell Park Comprehensive Cancer Center; and ³⁰National Comprehensive Cancer Network

*Discussion Writing Committee Member.

SYSTEMIC TREATMENT OF RECURRENT OR STAGE IV (M1) DISEASE

^c See Principles of Biomarker Testing (BINV-A*).

^{cc} Although patients with cancers with 1%–100% ER IHC staining are considered ER-positive and eligible for endocrine therapies, there are more limited data on the subgroup of cancers with ER-low–positive (1%–10%) results. The ER-low–positive group is heterogeneous with reported biologic behavior often similar to ER-negative cancers. This should be considered in decision-making for other adjuvant therapy and overall treatment pathway. See Principles of Biomarker Testing (BINV-A*).

*Available online, in these guidelines, at NCCN.org.

ⁿⁿⁿ The role and timing of surgical removal of the primary tumor in patients presenting with de novo stage IV (M1) is the subject of ongoing investigations and must be individualized. Performance of local breast surgery and/or RT is reasonable in select patients responding to initial systemic therapy.

^{ooo} Denosumab, zoledronic acid, or pamidronate (all with calcium and vitamin D supplementation) should be given (category 1) in addition to chemotherapy or endocrine therapy if bone metastasis is present, expected survival is ≥3 months, and renal function is adequate. Patients should undergo a dental examination with preventive dentistry prior to initiation of this therapy. The optimal schedule for zoledronic acid is every 12 weeks.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BINV-19

Overview

Breast cancer is the most common malignancy in women in the United States. The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article. The full NCCN Guidelines for Breast Cancer are available at NCCN.org. The primary goals of systemic treatment of recurrent/stage IV breast cancer are palliating symptoms, prolonging survival, and maintaining or improving quality of life. Hormone receptor (HR) status, human epidermal growth factor receptor 2 (HER2) overexpression, tumor burden, and patient preference are important factors in selecting appropriate therapeutic strategy for patients with recurrent/stage IV disease.

These guidelines have been developed by the NCCN Breast Cancer Panel. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. Although not stated at every decision point of the guidelines, patient participation in prospective clinical trials is the preferred option of treatment of all stages of breast cancer. For management of other clinical stages of breast cancer, please refer to the online version of the NCCN Guidelines at NCCN.org.

Management of Recurrent or Stage IV Disease

From the time of diagnosis of recurrent/stage IV metastatic disease, patients should be offered appropriate supportive care and symptom-related interventions as a routine part of their care. NCCN believes that the best management of any patient with cancer is in a clinical trial. Patients should be encouraged to participate in clinical trials whenever clinical trials are available.

Surgery for Recurrent or Stage IV Disease

The primary treatment approach recommended by the NCCN panel for women with metastatic breast cancer and an intact primary tumor is systemic therapy, with consideration of surgery after initial systemic treatment of those women requiring palliation of symptoms or with impending complications, such as skin ulceration, bleeding, fungation, and pain.¹ Generally, such surgery should be undertaken only if complete local clearance of tumor may be obtained and if other sites of disease are not immediately threatening to life. Alternatively, radiation therapy may be considered as an option to surgery. Often such surgery requires collaboration between the breast surgeon and the reconstructive surgeon to provide optimal cancer control and wound closure.

**SYSTEMIC TREATMENT OF RECURRENT OR STAGE IV (M1) DISEASE:
ER- AND/OR PR-POSITIVE; HER2-NEGATIVE^c**

^c See Principles of Biomarker Testing (BINV-A*).

^{PPP} See Definition of Menopause (BINV-O*).

^{qqq} See Systemic Therapy Regimens for Recurrent or Stage IV (M1) Disease (BINV-Q).

^{rrr} See Systemic Therapy for ER- and/or PR-Positive Recurrent or Stage IV (M1) Disease (BINV-P).

^{sss} If progression on initial endocrine therapy, switch to a different endocrine therapy option.

^{ttt} See Principles of Monitoring Metastatic Disease (BINV-S*).

*Available online, in these guidelines, at NCCN.org.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BINV-20

Retrospective studies suggest a potential survival benefit from complete excision of the in-breast tumor in select patients with metastatic breast cancer.²⁻⁵ Substantial selection biases exist in all of these studies and are likely to confound the study results.^{6,7}

Two prospective, randomized studies assessed whether surgery on the primary tumor in the breast is necessary for women who are diagnosed with metastatic/stage IV breast cancer.^{8,9} In the first prospective trial, women (n=350) with de novo metastatic breast cancer who experienced a partial or complete response to anthracycline-based chemotherapy were randomly assigned to either surgery of the primary tumor plus adjuvant radiation versus no locoregional treatment.⁸ There was no difference in the overall survival (OS) between the group that received surgery and the group that did not (19.2 vs 20.5 months; hazard ratio [HR] 1.04; 95% CI, 0.81–1.34).⁸ In a separate multiple center prospective registry study, women who responded to first-line systemic therapy were randomized to management of the primary tumor by surgery or not.¹⁰ Preliminary data showed no difference in OS between the 2 groups¹⁰

However, another trial by the Turkish Federation, MF07-01, of women (n=274) with de novo metastatic

breast cancer randomized to local management (mastectomy, or BCS with radiation) followed by systemic therapy versus systemic therapy only, observed a benefit with surgery.¹¹ Although no difference in survival was seen at 36 months, at 40 months, patients treated with local management showed an improvement in survival with locoregional treatment (46.4% vs 26.4%; HR, 0.66; 95% CI, 0.49–0.88).¹¹ The design of this trial is different from the other, the first being 2 prospective studies described previously in which patients were included only if they had experienced a response to systemic therapy. Second, randomization in the Turkish trial was not balanced. Patients who received surgery had lower rates of triple-negative disease (7% vs 17%) and visceral metastases (29% vs 45%), and many had solitary bone metastases only (33% vs 20%).¹¹ In an unplanned subgroup analysis, patients who appeared to derive the greatest OS benefit from local management included those with HR-positive disease (HR, 0.63; 95% CI, 0.44–0.89; *P*=.008); HER2-negative disease (HR, 0.64; 95% CI, 0.45–0.91; *P*=.01); those younger than 55 years (HR, 0.57; 95% CI, 0.38–0.86; *P*=.007); and those with solitary bone metastases (HR, 0.47; 95% CI, 0.23–0.98; *P*=.04).¹¹

**SYSTEMIC TREATMENT OF RECURRENT OR STAGE IV (M1) DISEASE:
ER- AND/OR PR-POSITIVE; HER2-NEGATIVE^{c,v}**

^c See Principles of Biomarker Testing (BINV-A*).

^v See Special Considerations for Breast Cancer in Men (BINV-J*).

^{eee} False-negative ER and/or PR determinations occur, and there may be discordance between the ER and/or PR determination between the primary and metastatic tumor(s). Therefore, endocrine therapy with its low attendant toxicity may be considered in patients with non-visceral or asymptomatic visceral tumors, especially in patients with clinical characteristics predicting for a hormone receptor-positive tumor (eg, long disease-free interval, limited sites of recurrence, indolent disease, older age).

^{qqq} See Systemic Therapy Regimens for Recurrent or Stage IV (M1) Disease (BINV-Q).

^{rrr} See Systemic Therapy for ER- and/or PR-Positive Recurrent or Stage IV (M1) Disease (BINV-P).

^{ttt} See Principles of Monitoring Metastatic Disease (BINV-S*).

^{uuu} If there is disease progression while on CDK4/6 inhibitor therapy, there are limited data to support an additional line of therapy with another CDK4/6-containing regimen. Likewise, if there is disease progression while on a everolimus-containing regimen, there are no data to support an additional line of therapy with another everolimus regimen.

^{vvv} The potential side effects of additional chemotherapy may outweigh any clinical benefit in a patient who has a compromised performance status. Patient preference must be taken into account.

*Available online, in these guidelines, at NCCN.org. †To view the most recent version of these guidelines, visit NCCN.org.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BINV-21

The panel recognizes the need for more data from randomized clinical trials that will address the risks and benefits of local therapy for patients with stage IV disease while eliminating selection biases. Although the available data does not support broadly considering local therapy with surgery and/or RT, this may be reasonable in select patients responding to initial systemic therapy. In such clinical scenarios, patient engagement in the decision is encouraged.

Guideline Stratification for Systemic Therapy for Stage IV/Recurrent Disease

The systemic treatment of breast cancer recurrence or stage IV disease prolongs survival and enhances quality of life (QOL) but is not curative. Therefore, treatments associated with minimal toxicity are preferred. Thus, the use of the minimally toxic endocrine therapies is preferred to the use of cytotoxic therapy whenever reasonable.¹² Guidance for treatment of patients with breast cancer and brain metastases is included in the NCCN Guidelines for Central Nervous System Cancers.

Patients with recurrent/stage IV breast cancer at diagnosis are initially stratified according to whether bone metastases are present. These 2 patient subsets

(those with and without bony metastases) are then stratified further by tumor HR and HER2 status.

Therapy for Bone Metastases

Complications from bone metastases include pain, decreased performance status, and decreased QOL, as well as skeletal-related events (SREs), which are defined as the need for radiation or surgery to bone, pathologic fractures, spinal cord compression, and hypercalcemia of malignancy.

The NCCN panel recommends treatment with a bone-modifying agent such as zoledronic acid, pamidronate, or denosumab (category 1) in addition to chemotherapy or endocrine therapy if bone metastasis is present; expected survival is ≥ 3 months. Patients should undergo a dental examination with preventive dentistry before starting this therapy. The bisphosphonates and denosumab are associated with a risk of development of osteonecrosis of the jaw (ONJ). Poor baseline dental health or dental procedures during treatment are known risk factors for ONJ. Thus, a dental examination with preventive dentistry intervention is recommended before treatment with intravenous bisphosphonate or denosumab, and dental procedures invasive of gum or

**SYSTEMIC TREATMENT OF RECURRENT OR STAGE IV (M1) DISEASE:
ER- and/or PR-POSITIVE; HER2-POSITIVE^c**

^c See Principles of Biomarker Testing (BINV-A*).

^{ppp} See Definition of Menopause (BINV-O*).

^{qqq} See Systemic Therapy Regimens for Recurrent or Stage IV (M1) Disease (BINV-Q).

^{rrr} See Systemic Therapy for ER- and/or PR-Positive Recurrent or Stage IV (M1) Disease (BINV-P).

^{ttt} See Principles of Monitoring Metastatic Disease (BINV-S*).

^{www} If treatment was initiated with chemotherapy and trastuzumab + pertuzumab, and the chemotherapy was stopped, endocrine therapy may be added to trastuzumab + pertuzumab.

*Available online, in these guidelines, at NCCN.org.

^{xxx} Fam-trastuzumab deruxtecan-nxki is indicated following two or more lines of prior HER2-targeted therapy in the metastatic setting. This agent is contraindicated for patients with pneumonitis or interstitial lung disease (ILD).

^{yyy} Trastuzumab given in combination with an anthracycline is associated with significant cardiac toxicity. Concurrent use of trastuzumab and pertuzumab with an anthracycline should be avoided.

^{zzz} If prior endocrine therapy within 1 y, consider a different endocrine therapy.

^{aaaa} For premenopausal women, selective ER modulators alone (without ovarian ablation/suppression) + HER2-targeted therapy is also an option.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BINV-22

bone during treatment should be avoided if at all possible. Additional risk factors for the development of ONJ include administration of chemotherapy or corticosteroids and poor oral hygiene with periodontal disease and dental abscess.¹³

Bisphosphonates

Extensive data from randomized trials exist that support the use of bisphosphonates for patients with metastatic disease to bone. The randomized clinical trial data include the use of zoledronic acid and pamidronate in the United States and ibandronate and clodronate in European countries.^{14–21} In metastatic bone disease, bisphosphonate treatment is associated with fewer SREs, fewer pathologic fractures, and less need for radiation therapy and surgery to treat bone pain.

The use of bisphosphonates in metastatic disease is a palliative care measure. No impact on OS has been observed in patients treated with bisphosphonates.

The data indicate that zoledronic acid and pamidronate may be given on a 3- to 4-week schedule in conjunction with antineoplastic therapy (ie, endocrine therapy, chemotherapy, biologic therapy) or every 12 weeks. Three randomized trials have compared zoledronic acid

dosed every 4 weeks versus every 12 weeks.^{22–24} Data from these trials show that among women with breast cancer and bone metastases, zoledronic acid administered once every 12 weeks versus once every 4 weeks does not compromise efficacy and has similar rates of SREs.^{22,23,25} In the ZOOM trial,²² the rate of skeletal morbidities was 0.22 (95% CI, 0.14–0.29) in those receiving zoledronic acid every 4 weeks and 0.26 (95% CI, 0.15–0.37) in those receiving zoledronic acid every 12 weeks. In the CALGB 70604 trial,²³ the SRE rate in the 4-week arm was 29.5% versus 28.6% in the 12-week arm. In the OPTIMIZE-2 trial,²⁴ the rate of SREs was 22% in the 4-week arm and 23.2% in the 12-week arm.²⁴ The panel recommends an optimal dosing of every 12 weeks.

The use of bisphosphonates should be accompanied by calcium and vitamin D supplementation with daily doses of calcium of 1,200 to 1,500 mg and vitamin D₃ of 400 to 800 IU. Recommended agents for use in the United States are pamidronate 90 mg intravenously over 2 hours or zoledronic acid 4 mg intravenously over 15 minutes. The original studies continued treatment of up to 24 months; however, there are limited long-term safety data indicating treatment can continue beyond that time.^{17,19,26} The risk of renal toxicity necessitates

**SYSTEMIC TREATMENT OF RECURRENT OR STAGE IV (M1) DISEASE:
ER- and/or PR-POSITIVE; HER2-POSITIVE^c**

^c See Principles of Biomarker Testing (BINV-A*).

^{eee} False-negative ER and/or PR determinations occur, and there may be discordance between the ER and/or PR determination between the primary and metastatic tumor(s). Therefore, endocrine therapy with its low attendant toxicity may be considered in patients with non-visceral or asymptomatic visceral tumors, especially in patients with clinical characteristics predicting for a hormone receptor-positive tumor (eg, long disease-free interval, limited sites of recurrence, indolent disease, older age).

^{qqq} See Systemic Therapy Regimens for Recurrent or Stage IV (M1) Disease (BINV-Q).

^{rrr} See Systemic Therapy for ER- and/or PR-Positive Recurrent or Stage IV (M1) Disease (BINV-P).

^{ttt} See Principles of Monitoring Metastatic Disease (BINV-S*).

^{xxx} Fam-trastuzumab deruxtecan-nxki is indicated following two or more lines of prior HER2-targeted therapy in the metastatic setting. This agent is contraindicated for patients with pneumonitis or interstitial lung disease (ILD).

^{yyy} Trastuzumab given in combination with an anthracycline is associated with significant cardiac toxicity. Concurrent use of trastuzumab and pertuzumab with an anthracycline should be avoided.

^{bbbb} Patients previously treated with chemotherapy plus trastuzumab in the absence of pertuzumab may be considered for one line of therapy including both trastuzumab plus pertuzumab in combination with or without cytotoxic therapy (such as vinorelbine or taxane). Further research is needed to determine the ideal sequencing strategy for anti-HER2 therapy.

^{cccc} Continue HER2-targeted therapy following progression on first-line HER2-targeted chemotherapy for metastatic breast cancer. The optimal duration of trastuzumab in patients with long-term control of disease is unknown.

^{ddd} The potential side effects of additional HER2-targeted therapy may outweigh any clinical benefit in a patient who has a compromised performance status. Patient preference must be taken into account.

*Available online, in these guidelines, at NCCN.org. [†]To view the most recent version of these guidelines, visit NCCN.org.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BINV-23

monitoring of serum creatinine before administration of each dose and dose reduction or discontinuation if renal function is reduced. Current clinical trial results support the use of bisphosphonates for up to 2 years. Longer durations of bisphosphonate therapy may provide additional benefit, but this has not yet been tested in clinical trials.

Denosumab

Women with metastatic breast cancer to bone who are candidates for bisphosphonate therapy may also be considered for treatment with denosumab. This recommendation is based on the results of a single randomized trial comparing denosumab to zoledronic acid.²⁷ All trial patients were recommended to supplement with vitamin D and calcium. Patients on the experimental arm were given 120 mg of denosumab injected subcutaneously every 4 weeks plus intravenous placebo versus the control arm where patients were given an intravenous infusion of 4 mg of zoledronic acid every 4 weeks, and a subcutaneous placebo. In this trial with noninferiority as the primary endpoint, denosumab was shown to significantly delay time to first SRE by 18% as compared with zoledronic acid (HR, 0.82; 95% CI, 0.71–0.95; $P < .001$

for noninferiority; $P = .01$ for superiority) and time to first and subsequent SREs (rate ratio, 0.77; 95% CI, 0.66–0.89; $P = .001$). No difference in time to progression or OS was observed.²⁷ Dosing of denosumab outside of every 3–6 weeks has not been studied.

Systemic Therapy for Stage IV or Recurrent Metastatic HR-Positive, HER2-Negative Breast Cancer

Women with stage IV or recurrent disease characterized by HR-positive, HER2-negative tumors with no visceral crisis are treated with endocrine therapy alone or endocrine therapy in combination with targeted agents.

Women whose disease progresses after a year from the end of adjuvant endocrine-based therapy and those who present with de novo stage IV/metastatic breast cancer are eligible for first-line endocrine therapies.

Many premenopausal and postmenopausal women with HR-positive breast cancer benefit from sequential use of endocrine therapies at disease progression. Therefore, women with breast cancers who respond to an endocrine-based therapy with either shrinkage of the tumor or long-term disease stabilization (clinical benefit) should receive additional endocrine therapy at disease

**SYSTEMIC TREATMENT OF RECURRENT OR STAGE IV (M1) DISEASE:
ER- and/or PR-NEGATIVE; HER2-POSITIVE^c**

^c See Principles of Biomarker Testing (BINV-A*).

^{qqq} See Systemic Therapy Regimens for Recurrent or Stage IV (M1) Disease (BINV-Q).

^{ttt} See Principles of Monitoring Metastatic Disease (BINV-S*).

^{xxx} Fam-trastuzumab deruxtecan-nxki is indicated following two or more lines of prior HER2-targeted therapy in the metastatic setting. This agent is contraindicated for patients with pneumonitis or interstitial lung disease (ILD).

^{yyy} Trastuzumab given in combination with an anthracycline is associated with significant cardiac toxicity. Concurrent use of trastuzumab and pertuzumab with an anthracycline should be avoided.

^{bbbb} Patients previously treated with chemotherapy plus trastuzumab in the absence of pertuzumab may be considered for one line of therapy including both trastuzumab plus pertuzumab in combination with or without cytotoxic therapy (such as vinorelbine or taxane). Further research is needed to determine the ideal sequencing strategy for anti-HER2 therapy.

^{cccc} Continue HER2-targeted therapy following progression on first-line HER2-targeted chemotherapy for metastatic breast cancer. The optimal duration of trastuzumab in patients with long-term control of disease is unknown.

^{ddd} The potential side effects of additional HER2-targeted therapy may outweigh any clinical benefit in a patient who has a compromised performance status. Patient preference must be taken into account.

*Available online, in these guidelines, at NCCN.org. †To view the most recent version of these guidelines, visit NCCN.org.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BINV-24

progression. Those who progress on or within 12 months of completing adjuvant endocrine therapy or patients who progress on first-line endocrine therapy for metastatic disease are eligible for second-line endocrine therapy either as monotherapy or in combination with a targeted agent. The optimal sequence for endocrine therapy is not well defined. The choice would depend on previous therapy, tolerance of treatment, and patient preference.

Many trials in patients with HR-positive cancer have not included premenopausal women. The NCCN panel recommends that women with HR-positive disease should have adequate ovarian suppression/ablation and then be treated in the same way as postmenopausal women. The NCCN panel has outlined endocrine-based therapies that would be used in the first-line versus second- and subsequent-line settings.

Preferred First-Line Therapy for HR-Positive, HER2-Negative Breast Cancer

Aromatase Inhibitor in Combination With Cyclin-Dependent Kinase 4/6 Inhibitor

In postmenopausal women or premenopausal women receiving ovarian ablation or ovarian function suppression with a luteinizing hormone-releasing hormone

agonist, combinations of aromatase inhibitors (AIs) with cyclin-dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) have demonstrated improved progression-free survival (PFS) relative to an AI alone.

Palbociclib in combination with letrozole was studied in a phase III study that included postmenopausal patients (n=666) with metastatic, HR-positive, HER2-negative breast cancer who had not received prior treatment of advanced disease.²⁸ An improvement in PFS (24.8 vs 14.5 months; HR, 0.58; 95% CI, 0.46–0.72) and objective response rate (ORR; 42% vs 35%) was seen with the combination of palbociclib and letrozole compared with letrozole alone.²⁸ Grade 3 and 4 adverse effects seen with the combination of palbociclib and letrozole included neutropenia (66.5% vs 1.4%), leukopenia (24.8% vs 0%), anemia (5.4% vs 1.8%), and fatigue (1.8% vs 0.5%).²⁸

Ribociclib in combination with letrozole was also studied as first-line therapy in a phase III study of postmenopausal women (n=668) with HR-positive, HER2-negative recurrent/stage IV breast cancer. At a median follow-up of 26.4 months, an improvement in PFS (25.3 vs 16.0 months; HR for progression or death was 0.56; 95% CI, 0.45–0.70) and improved ORR of 43% vs 29% was seen with ribociclib plus letrozole compared with

**SYSTEMIC TREATMENT OF RECURRENT OR STAGE IV (M1) DISEASE:
ER- AND/OR PR-NEGATIVE; HER2-NEGATIVE^c**

^c See Principles of Biomarker Testing (BINV-A*).

^{qqq} See Systemic Therapy Regimens for Recurrent or Stage IV (M1) Disease (BINV-Q).

^{ttt} See Principles of Monitoring Metastatic Disease (BINV-S*).

^{dddd} The potential side effects of additional chemotherapy may outweigh any clinical benefit in a patient who has a compromised performance status. Patient preference must be taken into account.

^{eeee} See Additional Targeted Therapies and Associated Biomarker Testing for Recurrent or Stage IV (M1) Disease (BINV-R).

*Available online, in these guidelines, at NCCN.org. [†]To view the most recent version of these guidelines, visit NCCN.org.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BINV-25

letrozole alone.²⁹ Grade 3 or 4 adverse events were more common with the combination, including neutropenia (62% vs 1.2%), leukopenia (21.3% vs 0.9%), and abnormal liver function tests (10.2% vs 2.4%).²⁹

The phase III MONARCH trial studied the combination of abemaciclib either with an AI (letrozole or anastrozole) versus AI monotherapy as first-line treatment of women with advanced HR-positive, HER2-negative breast cancer. The combination of abemaciclib with the AI improved PFS compared with AI alone (median not reached vs 14.7 months, respectively; HR, 0.54; 95% CI, 0.41–0.72).³⁰ The ORR was higher with the combination compared with AI monotherapy (59% vs 44%).³⁰ The most frequent grade 3 or higher adverse events for abemaciclib versus placebo included diarrhea (9.5% vs 1.2%), neutropenia (21.1% vs 1.2%), leukopenia (8% vs 0.6%), and fatigue (2% vs 0%).³⁰

Most trials studying CDK 4/6 inhibitor with an AI have mainly included postmenopausal women and only a small subset of premenopausal women on ovarian suppression. However, in the phase III MONALEESA-7 trial, 672 pre- or perimenopausal women with HR-positive, HER2-negative, advanced breast cancer were randomly assigned to first-line treatment with ribociclib or placebo

with goserelin plus either a nonsteroidal AI or tamoxifen.³¹ An improvement in PFS was seen with the addition of ribociclib (median PFS, 24 vs 13 months; HR, 0.55; 95% CI, 0.4–0.69).³¹

At 3.5 years, an improvement in OS was reported with ribociclib (70% vs 46%; HR, 0.71; 95% CI, 0.54–0.95).³² Grade 3 and 4 adverse events reported in greater than 10% of patients in either group included neutropenia (61% vs 4%), hot flashes (34% in each arm), and leukopenia (14% vs 1%).³¹

Based on the previously cited data, the NCCN panel has included AI in combination with CDK 4/6 inhibitors as a category 1 first-line option for postmenopausal women and premenopausal women with ovarian ablation/suppression with HR-positive, HER2-negative recurrent/stage IV breast cancer.

Single Agent Fulvestrant

Fulvestrant is an estrogen receptor (ER) antagonist and was originally approved as a monthly intramuscular injection (250 mg per month); higher dose has been proven to be more effective in subsequent randomized trials. In the first-line setting, fulvestrant was found to be as effective as anastrozole in terms of ORR (36.0%

SYSTEMIC THERAPY FOR ER- AND/OR PR-POSITIVE RECURRENT OR STAGE IV (M1) DISEASE

HER2-Negative and Postmenopausal or Premenopausal Receiving Ovarian Ablation or Suppression		HER2-Positive and Postmenopausal ^{f,g,h} or Premenopausal Receiving Ovarian Ablation or Suppression
Preferred Regimens First-Line Therapy <ul style="list-style-type: none">• Aromatase inhibitor + CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) (category 1)• Selective ER down-regulator (fulvestrant, category 1)^b ± non-steroidal aromatase inhibitor (anastrozole, letrozole) (category 1)^b• Fulvestrant + CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) (category 1)• Non-steroidal aromatase inhibitor (anastrozole, letrozole)• Selective estrogen receptors modulator (tamoxifen or toremifene)• Steroidal aromatase inactivator (exemestane)	Preferred Regimens Second- and Subsequent-Line Therapy <ul style="list-style-type: none">• Fulvestrant + CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) if CKD4/6 inhibitor not previously used (category 1)^a• For <i>PIK3CA</i>-mutated tumors, see additional targeted therapy options (see BINV-R)^c• Everolimus + endocrine therapy (exemestane, fulvestrant, tamoxifen)^{a,e}• Non-steroidal aromatase inhibitor (anastrozole, letrozole)• Steroidal aromatase inactivator (exemestane)• Selective ER down-regulator (fulvestrant)• Selective estrogen receptors modulator (tamoxifen or toremifene)	<ul style="list-style-type: none">• Aromatase inhibitor ± trastuzumab• Aromatase inhibitor ± lapatinib• Aromatase inhibitor ± lapatinib + trastuzumab• Fulvestrant ± trastuzumab• Tamoxifen ± trastuzumab
Useful in Certain Circumstances^c <ul style="list-style-type: none">• Megestrol acetate• Fluoxymesterone• Ethinyl estradiol• Abemaciclib^{a,d}		

^a If there is disease progression while on CDK4/6 inhibitor therapy, there are limited data to support an additional line of therapy with another CDK4/6-containing regimen. If there is disease progression while on a everolimus-containing regimen, there are no data to support an additional line of therapy with another everolimus regimen.

^b A single study (S0226) in women with hormone receptor-positive breast cancer and no prior chemotherapy, biological therapy, or endocrine therapy for metastatic disease demonstrated that the addition of fulvestrant to anastrozole resulted in prolongation of time to progression and overall survival. Subset analysis suggested that patients without prior adjuvant tamoxifen and more than 10 years since diagnosis experienced the greatest benefit. Two studies with similar design (FACT and SOFEA) demonstrated no advantage in time to progression with the addition of fulvestrant to anastrozole.

^c See Additional Targeted Therapies and Associated Biomarker Testing for Recurrent or Stage IV (M1) Disease (BINV-R).

^d Indicated after progression on prior endocrine therapy and prior chemotherapy in the metastatic setting.

^e A combination of exemestane with everolimus can be considered for patients who meet the eligibility criteria for BOLERO-2 (progressed within 12 mo or on non-steroidal aromatase inhibitor).

^f An FDA-approved biosimilar is an appropriate substitute for trastuzumab.

^g Trastuzumab and hyaluronidase-oysk injection for subcutaneous use may be substituted for trastuzumab. It has different dosage and administration instructions compared to intravenous trastuzumab. Do not substitute trastuzumab and hyaluronidase-oysk for or with ado-trastuzumab emtansine or fam-trastuzumab deruxtecan-nxki.

^h If treatment was initiated with chemotherapy and trastuzumab + pertuzumab, and the chemotherapy was stopped, endocrine therapy may be added to the trastuzumab + pertuzumab.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BINV-P

vs 35.5%; odds ratio, 1.02; 95% CI, 0.56–1.87).³³ An improved time to progression was seen with fulvestrant compared with anastrozole (median time to progression was 23.4 months for fulvestrant vs 13.1 months for anastrozole; HR, 0.63; 95% CI, 0.39–1.00; $P=.0496$).³⁴ This study also used a higher loading dose of 500 mg every 2 weeks for 3 doses and then maintenance dose of 500 mg monthly.³³ The median OS was observed to be longer in the fulvestrant group than in the anastrozole group (54.1 vs 48.4 months; HR, 0.70; $P=.041$).³⁵

A separate phase III randomized study in postmenopausal women with metastatic HR-positive breast cancer compared fulvestrant 500 mg every 2 weeks for 3 doses followed by 500 mg monthly versus fulvestrant 250 mg monthly. The PFS was superior with the fulvestrant 500 mg regimen (HR, 0.80; 95% CI, 0.68–0.94; $P=.006$),³⁶ indicating an increased duration of response with the higher dose of fulvestrant. The final analyses demonstrated an increase in median OS (4.1 months) and reduced risk of death (19%) with a dose of 500 mg compared with 250 mg. Median OS was 26.4 versus 22.3 months (HR, 0.81; 95% CI, 0.69–0.96; $P=.02$).³⁷

Results from another phase III trial (FALCON) of first-line treatment with fulvestrant compared with

anastrozole in endocrine therapy-naïve patients with metastatic ER-positive breast cancer, showed improved PFS with fulvestrant (at the higher dose, 500 mg) over anastrozole at a median follow-up of 25.0 months (16.6 vs 13.8 months, HR for progression or death, 0.797; 95% CI, 0.637–0.999).³⁸ The QOL outcomes were similar between the 2 groups, with the most common adverse effects being arthralgia (17% vs 10%) and hot flashes (11% vs 10%) for fulvestrant and anastrozole, respectively.³⁸

Fulvestrant + CDK 4/6 Inhibitor

In the phase III trial MONALEESA-3, patients (n=726) with advanced HR-positive breast cancer who had no prior endocrine therapy or had progressed on prior therapy, the combination of ribociclib with fulvestrant showed improved PFS versus fulvestrant alone (21 vs 13 months; HR, 0.59; 95% CI, 0.48–0.73).³⁹ The PFS benefits were consistent across patients with and without prior endocrine treatment. In a subsequent analysis, a significant improvement in OS was observed.⁴⁰ At 42 months, the estimated OS was 57.8% (95% CI, 52.0–63.2) in the ribociclib group and 45.9% (95% CI, 36.9–54.5) in the placebo group.⁴⁰

SYSTEMIC THERAPY REGIMENS FOR RECURRENT OR STAGE IV (M1) DISEASE^{a,b,c}

HER2-Negative	
Preferred Regimens	
<ul style="list-style-type: none"> • Anthracyclines <ul style="list-style-type: none"> ▶ Doxorubicin ▶ Liposomal doxorubicin • Taxanes <ul style="list-style-type: none"> ▶ Paclitaxel ▶ Anti-metabolites <ul style="list-style-type: none"> ▶ Capecitabine ▶ Gemcitabine • Microtubule inhibitors <ul style="list-style-type: none"> ▶ Vinorelbine ▶ Eribulin 	<ul style="list-style-type: none"> • For germline BRCA1/2 mutations^d see additional targeted therapy options (BINV-R)^e • Platinum (option for patients with triple-negative tumors and germline BRCA1/2 mutation)^d <ul style="list-style-type: none"> ▶ Carboplatin ▶ Cisplatin • For PD-L1–positive TNBC see additional targeted therapy options (BINV-R)^e
Other Recommended Regimens^f	
<ul style="list-style-type: none"> • Cyclophosphamide • Docetaxel • Albumin-bound paclitaxel 	<ul style="list-style-type: none"> • Epirubicin • Ixabepilone
Useful in Certain Circumstances^f	
<ul style="list-style-type: none"> • AC (doxorubicin/cyclophosphamide) • EC (epirubicin/cyclophosphamide) • CMF (cyclophosphamide/methotrexate/fluorouracil) • Docetaxel/capecitabine 	<ul style="list-style-type: none"> • GT (gemcitabine/paclitaxel) • Gemcitabine/carboplatin • Paclitaxel/bevacizumab^g • Carboplatin + paclitaxel or albumin-bound paclitaxel

^a Albumin-bound paclitaxel may be substituted for paclitaxel or docetaxel due to medical necessity (ie, hypersensitivity reaction). If substituted for weekly paclitaxel or docetaxel, then the weekly dose of nab-paclitaxel should not exceed 125 mg/m².

^b Consider scalp cooling to reduce incidence of chemotherapy-induced alopecia for patients receiving chemotherapy. Results may be less effective with anthracycline-containing regimens.

^c For treatment of brain metastases, see NCCN Guidelines for Central Nervous System Cancers.[†]

^d Assess for germline BRCA1/2 mutations in all patients with recurrent or metastatic breast cancer to identify candidates for PARP inhibitor therapy.

^e See Additional Targeted Therapies and Associated Biomarker Testing for Recurrent or Stage IV (M1) Disease (BINV-R).

^f Sequential single agents are preferred, but chemotherapy combinations may be used in select patients with high tumor burden, rapidly progressing disease, and visceral crisis.

^g Randomized clinical trials in metastatic breast cancer document that the addition of bevacizumab to some first- or second-line chemotherapy agents modestly improves time to progression and response rates but does not improve overall survival. The time-to-progression impact may vary among cytotoxic agents and appears greatest with bevacizumab in combination with weekly paclitaxel.

^h An FDA-approved biosimilar is an appropriate substitute for trastuzumab.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

HER2-Positive ^{h,i}	
Preferred regimens	
<ul style="list-style-type: none"> • Pertuzumab + trastuzumab + docetaxel (category 1)^j • Pertuzumab + trastuzumab + paclitaxel^l 	
Other recommended regimens	
<ul style="list-style-type: none"> • Ado-trastuzumab emtansine (T-DM1) • Fam-trastuzumab deruxtecan-nxki^k • Trastuzumab + paclitaxel^l ± carboplatin • Trastuzumab + docetaxel^l • Trastuzumab + vinorelbine^l • Trastuzumab + capecitabine • Lapatinib + capecitabine • Trastuzumab + lapatinib (without cytotoxic therapy) • Trastuzumab + other agents^{j,l,m} • Neratinib + capecitabine • See additional targeted therapy options (BINV-R)^e 	

ⁱ Trastuzumab and hyaluronidase-oysk injection for subcutaneous use may be substituted for trastuzumab. It has different dosage and administration instructions compared to intravenous trastuzumab. Do not substitute trastuzumab and hyaluronidase-oysk for or with ado-trastuzumab emtansine or fam-trastuzumab deruxtecan-nxki.

^j Patients previously treated with chemotherapy plus trastuzumab in the absence of pertuzumab in the metastatic setting may be considered for one line of therapy including both trastuzumab plus pertuzumab in combination with or without cytotoxic therapy (such as vinorelbine or taxane). Further research is needed to determine the ideal sequencing strategy for anti-HER2 therapy.

^k Fam-trastuzumab deruxtecan-nxki is indicated following two or more lines of prior HER2-targeted therapy in the metastatic setting. This agent is contraindicated for patients with pneumonitis or interstitial lung disease (ILD).

^l Trastuzumab given in combination with an anthracycline is associated with significant cardiac toxicity. Concurrent use of trastuzumab and pertuzumab with an anthracycline should be avoided.

^m Trastuzumab may be safely combined with all non-anthracycline containing preferred and other single agents listed above for recurrent or metastatic breast cancer.

[†]To view the most recent version of these guidelines, visit NCCN.org.

BINV-Q
1 OF 6

Comparison across multiple trials, including those in the second-line settings, studying the combination of fulvestrant with palbociclib or abemaciclib have shown statistically significant improvement in PFS. Based on the results of the Monaleesa-3 trial and extrapolation results from the second-line setting, the NCCN panel has included fulvestrant in combination with CDK 4/6 inhibitors as a category 1 first-line option for postmenopausal women and premenopausal women with ovarian ablation/suppression with HR-positive, HER2-negative recurrent/stage IV breast cancer.

Fulvestrant + Nonsteroidal AI

Combination of 2 endocrine agents as first-line treatment in postmenopausal women with HR-positive metastatic breast cancer has been reported from studies comparing single-agent anastrozole versus anastrozole plus fulvestrant.

In one study (FACT), combination of fulvestrant with anastrozole was not superior to single-agent anastrozole (time to progression HR, 0.99; 95% CI, 0.81–1.20; $P=.91$).⁴¹ In a second phase III trial (SoFEA), the effect of fulvestrant alone or in combination with anastrozole or exemestane was studied in patients with advanced

breast cancer with acquired resistance to a nonsteroidal AI.⁴² An AI had been given as adjuvant treatment to 18% of patients for a median of 27.9 months, and to 82% of patients for locally advanced/metastatic disease for a median of 19.3 months. Median PFS was 4.8 months, 4.4 months, and 3.4 months for patients treated with fulvestrant alone, anastrozole plus fulvestrant, and fulvestrant plus exemestane, respectively. No differences were observed for ORR, clinical benefit rate, and OS.

In the trial by the Southwest Oncology Group (SWOG), S0226, PFS (HR, 0.80; 95% CI, 0.68–0.94; stratified log-rank $P=.007$) and OS (HR, 0.81; 95% CI, 0.65–1.00; stratified $P=.049$) were superior with the combination of anastrozole plus fulvestrant.⁴³ A subgroup analysis in this trial suggested that patients without prior adjuvant tamoxifen experienced the greatest OS benefit with combination therapy compared with monotherapy (median, 52.2 vs 40.3 months, respectively; HR, 0.73; 95% CI, 0.58–0.92).⁴⁴

The reasons for the divergent outcomes in these trials are not very clear. The 3 trials discussed previously had slightly different patient populations. For example, there were more cases of patients with no prior endocrine exposure (with de novo stage IV metastatic disease) in the SWOG S0226 trial compared with the FACT trial.

**ADDITIONAL TARGETED THERAPIES AND ASSOCIATED BIOMARKER TESTING
FOR RECURRENT OR STAGE IV (M1) DISEASE**

Biomarkers Associated with FDA-Approved Therapies					
Breast Cancer Subtype	Biomarker	Detection	FDA-Approved Agents	NCCN Category of Evidence	NCCN Category of Preference
Any ^a	<i>BRCA1</i> mutation <i>BRCA2</i> mutation	Germline sequencing	Olaparib Talazoparib	Category 1 Category 1	Preferred Preferred
HR-positive/ HER2-negative ^b	<i>PIK3CA</i> mutation	PCR (blood or tissue block if blood negative), molecular panel testing	Alpelisib + fulvestrant ^d	Category 1	Preferred second-line therapy
HR-negative/ HER2-negative ^c	PD-L1 expression • Threshold for positivity: ≥1% on tumor-infiltrating immune cells	IHC	Atezolizumab + albumin-bound paclitaxel	Category 2A	Preferred
Any	<i>NTRK</i> fusion	FISH, NGS, PCR (tissue block)	Larotrectinib ^e Entrectinib ^e	Category 2A Category 2A	Useful in certain circumstances ^e Useful in certain circumstances ^e
Any	MSI-H/dMMR	IHC, PCR (tissue block)	Pembrolizumab ^f	Category 2A	Useful in certain circumstances ^f

^a Assess for germline *BRCA1/2* mutations in all patients with recurrent or metastatic breast cancer to identify candidates for PARP inhibitor therapy. While olaparib and talazoparib are FDA indicated in HER2-negative disease, the panel supports use in any breast cancer subtype associated with a germline *BRCA1* or *BRCA2* mutation.

^b For HR-positive/HER2-negative breast cancer, assess for *PIK3CA* mutations with tumor or liquid biopsy if HR-positive/HER2-negative and if considering therapy with to identify candidates for alpelisib plus fulvestrant. *PIK3CA* mutation testing can be done on tumor tissue or ctDNA in peripheral blood (liquid biopsy). If liquid biopsy is negative, tumor tissue testing is recommended.

^c For TNBC, assess PD-L1 expression biomarker status on tumor-infiltrating immune cells to identify candidates for atezolizumab plus albumin-bound paclitaxel.

^d The safety of alpelisib in patients with Type 1 or uncontrolled Type 2 diabetes has not been established.

^e Larotrectinib and entrectinib are indicated for the treatment of solid tumors that have an *NTRK* gene fusion without a known acquired resistance mutation and have no satisfactory alternative treatments or that have progressed following treatment.

^f Pembrolizumab is indicated for the treatment of patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Version 3.2020, 03/06/20 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

**BINV-R
1 OF 3**

The FACT trial included a more heterogeneous population of both premenopausal and postmenopausal women with locally advanced and metastatic disease. The SoFEA trial only enrolled patients with acquired endocrine resistance (who had disease progression while they were receiving an AI). Further studies are needed to confirm the results of the SWOG S0226 trial.

The NCCN panel has included an AI and fulvestrant as first-line therapy (category 1) for postmenopausal patients based on the previously noted data.

Monotherapy With Endocrine Agents

In postmenopausal women, there is evidence supporting the use of an AI as first-line therapy for recurrent disease.^{45,46} Prospective randomized trials comparing AIs head-to-head have shown that all AIs are the same.⁴⁷ Tamoxifen is the commonly used selective estrogen-receptor modulator (SERM) for premenopausal women.⁴⁸ In postmenopausal women, AI monotherapy has been shown to have superior outcome compared with tamoxifen, although the differences are modest.^{49–53} A randomized phase III trial comparing tamoxifen with exemestane as first-line endocrine therapy for postmenopausal women with metastatic breast cancer

showed no significant differences in PFS or OS between the 2 arms.⁵¹

NCCN Recommendations for First-Line Therapy

For postmenopausal women with HR-positive, HER2-positive recurrent/stage IV breast cancer, NCCN category 1 preferred regimens include a CDK 4/6 inhibitor with an AI; fulvestrant with or without a CDK 4/6 inhibitor; fulvestrant with a nonsteroidal AI. The NCCN category 2A preferred regimen includes nonsteroidal AIs (anastrozole, letrozole); steroidal AI (exemestane), and SERM (tamoxifen or toremifene). For premenopausal women, first-line endocrine treatment includes ovarian suppression/ablation and endocrine therapy listed previously for postmenopausal women or alternately with a SERM alone.

Preferred Regimens for Second and Subsequent Lines of Therapy for HR-Positive, HER2-Negative Breast Cancer

Fulvestrant-Containing Regimens

Fulvestrant + CDK 4/6 Inhibitors

Fulvestrant in combination with a CDK 4/6 inhibitor may be offered to patients who experienced progression

during prior treatment with AIs with or without 1 line of prior chemotherapy (category 1), because PFS was improved compared with fulvestrant alone in a phase III trial (PALOMA-3).⁵⁴ The NCCN panel notes that treatment should be limited to those *without* prior exposure to CDK 4/6 inhibitors.

The phase III trial (PALOMA-3) compared the combination of palbociclib and fulvestrant to fulvestrant in pre- or postmenopausal patients with HR-positive, HER2-negative advanced breast cancer whose disease progressed on prior endocrine therapy. Pre- or perimenopausal patients also received goserelin. The median PFS was 9.5 months for the combination compared with 4.6 months for fulvestrant (HR, 0.46; $P < .000001$).⁵⁵ Grade 3/4 adverse events of palbociclib and fulvestrant were mainly confined to neutropenia (in 65% of patients).

In the MONARCH 2 phase III trial, patients who had progressed while receiving endocrine therapy were randomly assigned to fulvestrant with or without abemaciclib.⁵⁶ Those receiving combination therapy experienced an improved PFS relative to those receiving fulvestrant alone (16.4 vs 9.3 months; HR, 0.55; 95% CI, 0.45–0.68). The ORR was higher in those receiving abemaciclib and fulvestrant (48% vs 21%).⁵⁶ In addition, an improvement was seen in OS with abemaciclib plus fulvestrant compared with fulvestrant alone (46.7 vs 37.3 months; HR, 0.757; 95% CI, 0.606–0.945).⁵⁷

Based on the previously cited data that shows that the addition of a CDK 4/6 inhibitor to fulvestrant in patients previously exposed to endocrine therapy provides a significant improvement in median PFS, the NCCN panel has included fulvestrant in combination with a CDK 4/6 inhibitor as a category 1 first-line option for postmenopausal women and premenopausal women with ovarian ablation/suppression with HR-positive, HER2-negative recurrent/stage IV breast cancer. The panel notes that if the disease progresses while on CDK4/6 inhibitor therapy, there are limited data to support an additional line of therapy with another CDK4/6-containing regimen.

Fulvestrant Monotherapy

Fulvestrant monotherapy appears to be at least as effective as anastrozole in patients whose disease progressed on previous tamoxifen.^{58,59} A randomized phase II study compared anastrozole versus fulvestrant in more than 200 patients with advanced breast cancer.^{33,34} In the initial analysis, fulvestrant was as effective as anastrozole in terms of ORR (36.0% vs 35.5%; odds ratio, 1.02; 95% CI, 0.56–1.87; $P = .947$) in evaluable patients ($n = 89$ for fulvestrant and $n = 93$ for anastrozole).³³ An improved time to progression was seen with fulvestrant compared with anastrozole (median time to progression was 23.4 months for fulvestrant vs 13.1 months for

anastrozole; HR, 0.63; 95% CI, 0.39–1.00; $P = .0496$).³⁴ This study used a higher, 500 mg, loading dose every 2 weeks for 3 doses and then 500 mg monthly.³³ The median OS was observed to be longer in the fulvestrant group than in the anastrozole group (54.1 vs 48.4 months; HR, 0.70; $P = .041$).³⁵

A phase II study of fulvestrant in postmenopausal women with advanced breast cancer and disease progression after AI therapy documented a partial response rate of 14.3% with an additional 20.8% of patients experiencing stable disease for at least 6 months.⁶⁰ The clinical benefit rates of exemestane versus fulvestrant observed in a phase III trial of postmenopausal women with HR-positive advanced breast cancer who experienced disease progression on prior nonsteroidal AI therapy were comparable (32.2% vs 31.5%; $P = .853$).⁶¹ In that study, fulvestrant was administered as a 500 mg loading dose followed by doses of 250 mg on day 14 and day 28 and then monthly.⁶¹

Fulvestrant Plus Alpelisib

In a randomized phase III trial of patients ($n = 572$) with advanced HR-positive breast cancer and confirmed phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA*) mutated tumors, all of whom had received a prior AI either for local or advanced disease, patients were randomized to receive fulvestrant plus the phosphoinositide 3-kinase (PI3K) inhibitor, alpelisib versus fulvestrant plus placebo. Patients receiving alpelisib showed improved PFS compared with fulvestrant alone. At a median follow-up of 20 months, PFS was 11.0 months (95% CI, 7.5–14.5) in the alpelisib group compared with 5.7 months (95% CI, 3.7–7.4) in the group that received fulvestrant alone (HR for progression or death, 0.65; 95% CI, 0.50–0.85; $P < .001$); in the cohort without *PIK3CA*-mutated tumors, the HR was 0.85 (95% CI, 0.58–1.25). In the overall population, the most frequently reported grade 3 or 4 adverse events seen with alpelisib and fulvestrant versus fulvestrant alone were hyperglycemia (36.6% vs 0.7%); rash (9.9% vs 0.3%) and diarrhea (grade 3; 6.7% vs 0.3%; no diarrhea of grade 4 was reported).⁶²

Everolimus Plus Endocrine Therapy

Resistance to endocrine therapy in women with HR-positive disease is frequent. One mechanism of resistance to endocrine therapy is activation of the mammalian target of rapamycin (mTOR) signal transduction pathway.

A randomized phase II study estimated the efficacy of tamoxifen alone versus tamoxifen combined with everolimus, an oral inhibitor of mTOR, in women with HR-positive, HER2-negative metastatic breast cancer previously treated with an AI.⁶³ After a median follow-up

of 13 months, an intent-to-treat analysis showed that the clinical benefit was 42.1% (95% CI, 29.1–55.9) with tamoxifen alone and 61.1% (95% CI, 46.9–74.1) with tamoxifen plus everolimus. An improvement in median time to progression was seen when everolimus was combined with tamoxifen compared with tamoxifen alone. Median time to progression was 4.5 months (95% CI, 3.7–8.7) with tamoxifen alone versus 8.5 months (95% CI, 6.01–13.9) with everolimus and tamoxifen.⁶³

A phase III trial in postmenopausal women with advanced, HR-positive breast cancer with no prior endocrine therapy for advanced disease that randomized subjects to letrozole with or without the mTOR inhibitor temsirolimus has been reported.⁶⁴ In this study, PFS was not different between the treatment arms (HR, 0.89; 95% CI, 0.75–1.05; long-rank $P=.18$).

The results of this trial differ from that of the BOLERO-2 trial (described subsequently). The reasons for the differences in the outcomes of these 2 randomized phase III studies^{64,65} is uncertain, but may be related to the issues of patient selection and extent of prior endocrine therapy.

A phase III study (BOLERO-2) randomized postmenopausal women with HR-positive advanced breast cancer that had progressed or recurred during treatment with a nonsteroidal AI to exemestane with or without the mTOR inhibitor everolimus.⁶⁶ Final results reported after median 18-month follow-up show that median PFS (by central review) remained significantly longer with everolimus plus exemestane versus placebo plus exemestane at 11.0 versus 4.1 months, respectively; (HR, 0.38; 95% CI, 0.31–0.48; $P<.0001$).⁶⁵ The adverse events (all grades) that occurred more frequently in those receiving everolimus included stomatitis, infections, rash, pneumonitis, and hyperglycemia.^{65,66} Analysis of safety and efficacy in the elderly patients enrolled in this trial showed that elderly patients treated with an everolimus-containing regimen had similar incidences of these adverse events, but the younger patients had more on-treatment deaths.⁶⁷ Based on the evidence from the BOLERO-2 trial, the NCCN panel has included everolimus plus exemestane as an option for women who fulfill the entry criteria for BOLERO-2. Tamoxifen or fulvestrant in combination with everolimus have also been included as options. The NCCN panel also notes that if there is disease progression while on an everolimus-containing regimen, there are no data to support an additional line of therapy with another everolimus regimen.

Aromatase Inhibitors

AIs as monotherapy are options as subsequent-line therapy. The 3 AIs (anastrozole, letrozole, and exemestane) have shown similar efficacy in the second-line

setting.^{47,68,69} AI monotherapy maybe be useful in patients desiring single-agent treatment, if they have not received an AI as first-line treatment or in patients who may not be suitable for combination therapy. Patients who have received a prior nonsteroidal AI may benefit from a steroidal AI as subsequent-line therapy or vice-versa.

Selective Estrogen Receptor Modulator

An analysis of 2 randomized studies of first-line treatment with anastrozole followed by second-line tamoxifen and vice versa showed that tamoxifen is effective as a second-line option.⁷⁰

NCCN Recommendations for Second-Line Treatment

For postmenopausal women with HR-positive, HER2-positive recurrent/stage IV breast cancer, the preferred options available include fulvestrant with a CDK 4/6 inhibitor (palbociclib, ribociclib, abemaciclib) (category 1), or for those with tumor *PIK3CA* mutations, fulvestrant with alpelisib, everolimus with either an AI, tamoxifen, or fulvestrant; monotherapy with fulvestrant, nonsteroidal or steroidal AI, or SERM. Estrogen receptor 1-activating mutations are frequently detected in patients with prior exposure to AIs. Tumors with these mutations are generally resistant to both AIs and tamoxifen. Certain tumors with these mutations retain sensitivity to fulvestrant. All may benefit from the addition of a CDK 4/6 inhibitor, mTOR inhibitor, or alpelisib in combination with fulvestrant if the tumor has a *PIK3CA* mutation.

Regimens Useful in Certain Circumstances for Therapy for HR-Positive, HER2-Negative Breast Cancer

Megestrol acetate,^{45,71–73} estradiol⁷⁴ androgens such as fluoxymesterone, and single agent abemaciclib have been listed as options useful in certain circumstances. The phase II MONARCH 1 trial evaluated the activity of abemaciclib as a single agent in patients (n=132) with refractory HR-positive, HER2-negative metastatic breast cancer who had progressed on endocrine therapy and already received multiple systemic therapies (average of 3 prior systemic regimens).⁷⁵ Ninety percent of patients had visceral disease, and 50.8% had more than 3 sites of metastases.⁷⁵ Single-agent abemaciclib induced partial response in 26 (19.7%) and demonstrated an ORR of 19.7% (95% CI: 13.3–27.5).⁷⁵ Median PFS was 6 months (95% CI: 4.2–7.5). At the final analysis, at 18 months, median OS was 22.3 months (95% CI: 17.7–not reached).⁷⁵ Diarrhea was the most frequent adverse event, reported in 90.2% of patients. Other common adverse events were fatigue (65.2%), nausea (64.4%), and decreased appetite (45.5%). Grade 3 and 4 neutropenia occurred in 26.9% of patients.⁷⁵ The NCCN panel has included single-agent

abemaciclib as an option for those with disease progression on prior endocrine therapy and prior chemotherapy in the metastatic setting.

Systemic Therapy for Stage IV or Recurrent HR-Negative, HER2-Positive Breast Cancer

For patients with HER2-positive, HR-negative recurrent/stage IV breast cancer, the treatment approach is HER2-targeted therapy in combination with systemic chemotherapy. The NCCN panel notes that an FDA-approved biosimilar is an appropriate substitute for trastuzumab. Also, trastuzumab and hyaluronidase-oysk injection for subcutaneous use may be substituted for trastuzumab. This subcutaneous option has different dosage and administration instructions compared with intravenous trastuzumab. Doses and schedules of representative regimens for use in HER2-positive metastatic breast cancer are also included in NCCN Guidelines.

Patients progressing on a HER2-targeted therapy should be offered additional subsequent treatment with a HER2-targeted therapy since it is beneficial to continue suppression of the HER2 pathway. The choice of the HER2-targeted therapy will depend on previously administered therapy, relapse-free interval, and patients' preference and access.

The optimal sequence of available HER2-targeted therapies and the optimal duration of HER2-targeted therapy for recurrent/stage IV is currently unknown. The NCCN panel recommends continuing HER2-targeted therapy until progression or unacceptable toxicity.

Preferred Regimens for Stage IV/Recurrent HER2-Positive Breast Cancer

A randomized, double-blind, phase III study (CLEOPATRA) compared the efficacy and safety of pertuzumab in combination with trastuzumab and docetaxel versus trastuzumab and docetaxel as first-line treatment of 808 women (n=808) with HER2-positive metastatic breast cancer.⁷⁶ This trial included patients (about 10%) who had previously received trastuzumab in the adjuvant or neoadjuvant setting. At a median follow-up of 19 months, the addition of pertuzumab to docetaxel plus trastuzumab resulted in improvement in PFS compared with placebo (median, 18.5 vs 12.4 months; HR, 0.62; 95% CI, 0.51-0.75; $P<.001$).⁷⁶ At a median follow-up of 30 months, the results showed a statistically significant improvement in OS in favor of the pertuzumab-containing regimen, with a 34% reduction in the risk of death (HR, 0.66; 95% CI, 0.52-0.84; $P=.0008$).⁷⁷ The most common adverse reactions reported in the pertuzumab group compared with the control group were diarrhea (67% vs 46%), rash (34% vs 24%), mucosal inflammation (27% vs 20%), febrile neutropenia (14% vs 8%), and dry skin (10% vs 4%). Peripheral edema and constipation

were greater in the control group.⁷⁶ Cardiac adverse events or left ventricular systolic dysfunction were reported slightly more frequently in the control group.⁷⁸ Health-related QOL was not different in the 2 treatment groups.⁷⁹ In the PERUSE study, patients (n=1,436) with advanced HER2-positive breast cancer and no prior systemic therapy (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab, and pertuzumab until disease progression or unacceptable toxicity. The preliminary results after 52 months median follow-up show that median PFS was comparable between docetaxel, paclitaxel, and nab-paclitaxel (median PFS reported was 19.6, 23.0, and 18.1 months with docetaxel, paclitaxel, and nab-paclitaxel, respectively).⁸⁰ Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (31% vs 16%) but less febrile neutropenia (1% vs 11%) and mucositis (14% vs 25%).

Phase II trials have also found activity and tolerability for pertuzumab, pertuzumab with trastuzumab, and for other regimens combining pertuzumab and trastuzumab together with other active cytotoxic agents (ie, paclitaxel, vinorelbine).⁸¹⁻⁸³ Phase III trials of pertuzumab plus chemotherapy without trastuzumab have not been reported.

The NCCN panel recommends pertuzumab plus trastuzumab in combination with a taxane as a preferred option for first-line treatment of patients with HER2-positive metastatic breast cancer. Pertuzumab plus trastuzumab in combination with docetaxel is an NCCN category 1 and in combination with paclitaxel is an NCCN category 2A recommendation.

Other Regimens for Stage IV/Recurrent HER2-Positive Breast Cancer

Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that stably links the HER2-targeting property of trastuzumab to the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine).

In a phase III trial (MARIANNE), 1,095 patients with locally advanced or metastatic breast cancer were randomized to first-line treatment with T-DM1 with or without pertuzumab or trastuzumab plus a taxane. The primary endpoints were safety and PFS assessed by independent review. The PFS for T-DM1 with pertuzumab was found noninferior to trastuzumab and a taxane (15.2 and 13.7 months respectively; HR, 0.87; 97.5% CI, 0.69-1.08; $P=.14$).⁸⁴ The PFS for T-DM1 alone was noninferior to trastuzumab plus a taxane (14.1 and 13.7, respectively; HR, 0.91; 97.5% CI, 0.73-1.13; $P=.31$).⁸⁴ The incidence of grade 3-5 adverse events was 54.1%, 45.4%, and 46.2% in the trastuzumab plus a taxane arm, T-DM1 arm, and T-DM1 plus pertuzumab arm, respectively.

Health-related QOL was maintained for a longer duration with a median of 7.7 months for T-DM1 (HR, 0.70; 95% CI, 0.57–0.86) and a median of 9 months for T-DM1 plus pertuzumab (HR, 0.68; 95% CI, 0.55–0.84) compared with a median of 3.9 months for trastuzumab and a taxane.⁸⁴

Based on the MARIANNE trial data demonstrating T-DM1 and T-DM1 with pertuzumab being noninferior, with better QOL compared with trastuzumab plus taxane and possibly better-tolerated for some patients,⁸⁴ the NCCN panel included T-DM1 as an option for treatment of patients with HER2-positive metastatic breast cancer. Pertuzumab, trastuzumab, and a taxane, however, remains the preferred first-line regimen for HER2-positive metastatic disease based on data demonstrating improved OS compared with trastuzumab and a taxane. TDM-1 as first-line therapy should be considered only in those not suitable for the preferred treatment.

First-line trastuzumab in combination with selected chemotherapy⁸⁵ is an additional option for patients with HER2-positive metastatic breast cancer. Randomized trials demonstrate benefit from adding trastuzumab to other agents including paclitaxel with or without carboplatin,^{85–88} docetaxel,⁸⁶ and vinorelbine,⁸⁶ for patients with HER2-positive metastatic disease. In addition, the combination of trastuzumab and capecitabine has also shown efficacy as a first-line trastuzumab-containing regimen in this setting.^{89,90} The NCCN panel believes the 27% frequency of significant cardiac dysfunction in patients treated with the combination of trastuzumab and doxorubicin/cyclophosphamide chemotherapy in the metastatic setting is too high for use of this combination outside the confines of a prospective clinical trial.^{85,90,91}

In those with disease progression on first-line trastuzumab-containing regimens, the NCCN panel recommends continuation of HER2 blockade. This recommendation also applies to patients who are diagnosed with HER2-positive metastatic disease after prior exposure to trastuzumab in the adjuvant setting. Several trials have demonstrated benefit of continuation of trastuzumab therapy after disease progression on a trastuzumab-containing regimen.^{92–94} However, the optimal duration of trastuzumab in patients with long-term control of disease is unknown.

Pertuzumab is active in patients beyond the first-line setting. The results of a multicenter, open-label, single-arm, phase II study (n=66) show that the combination of pertuzumab and trastuzumab is active and well tolerated in patients with HER2-positive metastatic breast cancer that has progressed on prior trastuzumab therapy.⁹⁵ The trial reported an objective response rate of 24.2% (16 patients out of 66). The median PFS time observed with pertuzumab and trastuzumab

combination was 15.5 months (range, 0.9–17.0 months; 80% CI, 18–31 months).⁹⁵ The reported median duration of response with the combination was 5.8 months (range, 2.9–15.3 months).⁹⁵

To determine whether the clinical benefit seen in the study was from pertuzumab alone or was a result of the combined effect of pertuzumab and trastuzumab, a cohort of patients (n=29) whose disease progressed during prior trastuzumab-based therapy received pertuzumab monotherapy until progressive disease or unacceptable toxicity. Of these, patients with disease progression (n=17) continued to receive pertuzumab with the addition of trastuzumab. In the 29 patients who received pertuzumab monotherapy, the objective response rate and clinical benefit rate reported were 3.4% and 10.3%, respectively, whereas in the patients who received dual blockade after progression on pertuzumab, the objective response rate and clinical benefit rate were 17.6% and 41.2%, respectively.⁹⁶

According to the NCCN panel, for patients with disease progression after treatment with trastuzumab-based therapy without pertuzumab, a line of therapy containing both trastuzumab plus pertuzumab with or without a cytotoxic agent (such as vinorelbine or taxane) may be considered. Further research is needed to determine the ideal sequencing strategy for HER2-targeted therapy.

T-DM1 also has also shown activity in the second-line setting. A randomized, international, multicenter, open-label, phase III study (EMILIA) evaluated the safety and efficacy of T-DM1 compared with lapatinib plus capecitabine for patients with HER2-positive locally advanced breast cancer or metastatic breast cancer previously treated with trastuzumab and a taxane.⁹⁷ The primary endpoints of this study were PFS, OS, and safety. T-DM1 demonstrated a statistically significant improvement in both primary endpoints of PFS and OS. PFS (assessed by independent review) was significantly improved with T-DM1, with a median PFS of 9.6 months vs 6.4 months with lapatinib plus capecitabine; HR for progression or death from any cause was 0.65 (95% CI, 0.55–0.77; $P<.001$). At the first interim analysis, T-DM1 also demonstrated significant improvement in OS. The stratified HR for death from any cause with T-DM1 versus lapatinib plus capecitabine was 0.62 (95% CI, 0.48–0.81; $P=.0005$).⁹⁷ Rates of grade 3 or 4 adverse events were higher with lapatinib plus capecitabine than with T-DM1 (57% vs 41%). The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1 (frequency >25%), whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.⁹⁷

A phase II single-arm study evaluated fam-trastuzumab deruxtecan-nxki, a HER2 antibody conjugated with a

topoisomerase I inhibitor, in adults (n=184) with pathologically documented HER2-positive metastatic breast cancer who had received multiple previous treatments including treatment with T-DM1.⁹⁸ After a median duration of follow-up of 11.1 months (range 0.7–19.9), the median response duration with fam-trastuzumab deruxtecan-nxki was 14.8 months (95% CI, 13.8–16.9), and the median PFS was 16.4 months (95% CI, 12.7–not reached).⁹⁸ Most commonly reported adverse events (grade 3 or higher) were a decreased neutrophil count (20.7%), anemia (in 8.7%), nausea (in 7.6%), and fatigue (6%).⁹⁸ Interstitial lung disease was reported in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). Based on this study and the approval from the US FDA, the NCCN panel has included this as an option for HER-2 positive metastatic disease noting that it is indicated in patients after 2 or more lines of prior HER2-targeted therapy regimens in the metastatic setting and contraindicated for those with a history of or active interstitial lung disease.

Lapatinib in combination with capecitabine or trastuzumab are options for patients with HER2-positive disease after progression on a trastuzumab-containing regimen.

A phase III study compared lapatinib plus capecitabine with capecitabine alone in women with advanced or metastatic breast cancer refractory to trastuzumab in the metastatic setting and with prior treatment with an anthracycline and a taxane in either the metastatic or adjuvant setting.⁹⁹ Time to progression was increased in the group receiving combination therapy when compared with the group receiving capecitabine monotherapy (8.4 vs 4.4 months; HR, 0.49; 95% CI, 0.34–0.71; $P < .001$). The patients who progressed on monotherapy were allowed to cross over to the combination arm. This resulted in insufficient power to detect significant differences in OS; an exploratory analysis showed a trend toward a survival advantage with lapatinib plus capecitabine.¹⁰⁰ The analysis reported a median OS of 75.0 weeks for the combination arm and 64.7 weeks for the monotherapy arm (HR, 0.87; 95% CI, 0.71–1.08; $P = .210$).¹⁰⁰

Results from a phase III trial in which patients with heavily pretreated metastatic breast cancer and disease progression on trastuzumab therapy randomly assigned to trastuzumab plus lapatinib or lapatinib monotherapy showed that PFS was increased from 8.1 weeks to 12 weeks ($P = .008$) with the combination.¹⁰¹ The OS analysis data showed that lapatinib plus trastuzumab improved median survival by 4.5 months, with median OS of 14 months for the combination therapy and 9.5 months for lapatinib alone (HR, 0.74; 95% CI, 0.57–0.97; $P = .026$).¹⁰² This improvement in OS analysis included patients who were initially assigned to monotherapy and crossed over

to receive combination therapy at the time of progression.¹⁰² Based on the absence of data, the panel does not recommend the addition of chemotherapy to the trastuzumab and lapatinib combination.

In a phase II trial, patients (n=49) with progressive, HER2-positive disease and brain metastases (92% received central nervous system surgery and/or radiotherapy),¹⁰³ were treated with capecitabine plus neratinib, a second-generation (irreversible) pan-HER TKI inhibitor of the tyrosine kinase domains of EGFR, HER2 and HER4. The patients were separated based on prior lapatinib treatment. The combination therapy resulted in a central nervous system objective response rate of 49% (95% CI, 32%–66%), among lapatinib-naïve patients, and 33% (95% CI, 10%–65%) among those with prior lapatinib treatment.¹⁰³ Median PFS and OS among lapatinib-naïve patients was 5.5 and 13.3 months, and 3.1 and 15.1 months among those with prior lapatinib treatment. Grade 3 diarrhea occurred in 29% of patients.¹⁰³

A prospective randomized phase III trial (NALA) randomized patients (n=621) with HER2-positive disease to neratinib in combination with capecitabine or lapatinib plus capecitabine until disease progression.¹⁰⁴ All enrolled patients received ≥ 2 lines of prior HER2-targeted treatment in the metastatic setting. Approximately 30% had received ≥ 3 prior treatment lines. About a third of all patients had received prior treatment with trastuzumab, pertuzumab, and T-DM1.

The ORR (32.8% vs 26.7%; $P = .1201$), the clinical benefit rate (44.5% vs 35.6%; $P = .0328$), and median duration of response (8.5 vs 5.6 months) all favored the neratinib arm. Fewer patients required intervention for central nervous system metastases with neratinib. The risk of progression was reduced by 24% in the neratinib group (HR, 0.76; 95% CI, 0.63–0.93; $P = .0059$). There was a nonsignificant trend toward improved survival. The OS rates at 6 and 12 months were 90.2% vs 87.5% with neratinib plus capecitabine compared with 72.5% vs 66.7% for lapatinib in combination with capecitabine (HR, 0.88; 95% CI, 0.72–1.07; $P = .2086$). Diarrhea was the most frequent side effect in the NALA trial in both arms, but a higher rate was observed in patients in the neratinib group (any grade diarrhea, 83% vs 66%; grade 3/4 diarrhea, 24% vs 13%). Based on the results of the NALA trial and the recent FDA approval, NCCN has included neratinib plus capecitabine as a category 2A option in this setting.

Systemic Therapy for Recurrent or Stage IV HR-Positive, HER2-Positive Breast Cancer

Women with stage IV or recurrent disease characterized by HR-positive, HER2-positive tumors have the option of receiving HER2-directed therapy as a component of their treatment plan. Options include treatment with a

HER2-targeted therapy plus chemotherapy or endocrine therapy alone or in combination with HER2-targeted therapy. Endocrine therapy alone or in combination with HER2-targeted therapy is a less toxic approach compared with HER2-targeted therapy combined with chemotherapy. Premenopausal women treated with HER2-targeted therapy and endocrine therapy should receive ovarian suppression or ablation.

Adding trastuzumab or lapatinib to an AI has demonstrated a PFS advantage compared with AI alone in postmenopausal women with stage IV or recurrent HR-positive, HER2-positive tumors.

In the TAnDEM study, postmenopausal women (n=207) with metastatic HR-positive and HER2-positive tumors were randomized to receive anastrozole alone or anastrozole plus trastuzumab.¹⁰⁵ Compared with single-agent anastrozole, an improvement in PFS was seen with combination therapy (4.8 vs 2.4 months; HR, 0.63; 95% CI, 0.47–0.84; $P=.0016$). The combination was associated with a higher incidence of toxicities (all grades), fatigue (21% vs 9%), diarrhea (20% vs 8%), vomiting (21% vs 4%), and pyrexia (18% vs 7%); serious (grade 3/4) toxicities were rare in both treatment arms.

The phase III eLEcTRA trial studied the efficacy and safety of trastuzumab plus letrozole in patients (n=93) with HER2-positive and HR-positive metastatic breast cancer. Median time to progression was 3.3 months with letrozole and 14.1 months with trastuzumab plus letrozole. The results are consistent with the TAnDEM trial; however, due to smaller numbers of patients enrolled in this trial, this was not statistically significant (HR, 0.67; 95% CI, 0.35 to 1.29; $P=.23$).¹⁰⁶

In a phase III study of postmenopausal patients (n=219) with HER2-positive and HR-positive disease, first-line treatment with lapatinib plus letrozole reduced the risk of disease progression compared with treatment with letrozole alone (median PFS, 8.2 vs 3.0 months; HR, 0.71, 95% CI, 0.53–0.96; $P=.019$).¹⁰⁷ The combination of letrozole plus trastuzumab was associated with a higher rate of grade 3 or 4 toxicities, including diarrhea (10% vs 1%) and rash (1% vs 0%).¹⁰⁷

In a randomized phase II study (PERTAIN), postmenopausal women (n=258) were randomly assigned to either first-line pertuzumab plus trastuzumab and an AI (anastrozole or letrozole) or trastuzumab plus an AI. Results showed an improvement in PFS with the 3-drug combination (18.9 vs 15.8 months; HR, 0.65; 95% CI, 0.48–0.89).¹⁰⁸ Grade 3 or higher adverse events observed were higher with trastuzumab and pertuzumab versus pertuzumab alone (50% vs 39%). Of note, about half of women received induction therapy with a taxane for 18 to 24 weeks before the start of endocrine therapy. Based on the results of the PERTAIN trial,¹⁰⁸ the NCCN panel notes that if treatment was initiated with chemotherapy and

trastuzumab plus pertuzumab and the chemotherapy was stopped, endocrine therapy may be added to the trastuzumab plus pertuzumab.

In the ALTERNATIVE trial, postmenopausal women (n=355) with HER2-positive, HR-positive metastatic breast cancer were randomized to receive lapatinib plus trastuzumab plus an AI, lapatinib plus an AI, or trastuzumab plus AI without chemotherapy.¹⁰⁹ All patients in the trial received prior trastuzumab and prior endocrine therapy, either in the adjuvant or metastatic disease setting. AI in combination with lapatinib plus trastuzumab demonstrated significant increase in PFS compared with trastuzumab without lapatinib (11 vs 5.7 months; HR, 0.62; 95% CI, 0.45–0.88; $P=.0064$).¹⁰⁹ Most common adverse events with the combination compared with trastuzumab or lapatinib monotherapy were diarrhea (69%, 9%, 51%), rash (36%, 2%, 28%), nausea (22%, 9%, 22%), and paronychia (30%, 0%, 15%).

The NCCN panel has also included other combinations of available endocrine therapies such as fulvestrant or tamoxifen with trastuzumab as options for HR-positive and HER2-positive metastatic disease. These options would be mostly considered after completion of chemotherapy plus HER2-therapy or in a few patients with indolent or asymptomatic disease based on the need for continuing HER2-targeted therapy for disease control. The selection of appropriate endocrine therapy would depend on agents the patient has already received and/or progressed on.

Systemic Therapy for Recurrent or Stage IV Disease With Germline BRCA1/2 Mutations

About 5% of all patients with breast cancer carry the germline breast cancer susceptibility gene (*BRCA*) mutations and rates of these mutations are higher among those with HER2-negative disease.^{110,111}

Poly (ADP-Ribose) Polymerase Inhibitors

The phase III OlympiAD trial randomized patients (n=302) with metastatic breast cancer harboring the germline *BRCA* mutations to the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib (n=205), or physician's choice (n=97) of nonplatinum chemotherapy (capecitabine, eribulin, or vinorelbine).¹¹² An improvement in PFS was seen in those receiving olaparib relative to those receiving chemotherapy (7.0 vs 4.2 months; HR, 0.58; 95% CI, 0.43–0.80; $P<.001$).¹¹² The study included all subtypes: those with HR-positive, HER2-negative and -positive, and triple-negative disease. The PFS improvements noted with olaparib were noted in all subtypes and greatest in the triple-negative population. Subsequent follow-up did not show a statistically significant difference in OS between treatment arms, and the study was also not powered to evaluate OS. The median OS with olaparib compared with treatment of physician's choice

was 19.3 months versus 17.1 months, respectively (HR, 0.90; 95% CI, 0.66–1.23; $P=.513$).¹¹³ QOL was significantly better in the olaparib arm. It is interesting to note that patients who had not received prior chemotherapy in the metastatic setting achieved a 7.9-month longer median OS compared with treatment of physician's choice.¹¹³

In the phase III EMBRACA trial, patients with advanced breast cancer harboring the germline *BRCA* mutations to a PARP inhibitor were randomized to talazoparib ($n=287$) or to physician's choice of single-agent chemotherapy ($n=144$).¹¹⁴ The median PFS among patients in the talazoparib group was longer than the control group (8.6 months [95% CI, 7.2–9.3] vs 5.6 months [95% CI, 4.2–6.7]; HR for disease progression or death, 0.54; 95% CI, 0.41 to 0.71; $P<.001$).¹¹⁴ The comparator arms of OlympiAD and EMBRACA did not include patients previously treated with either taxanes or platinum agents.

Based on the results of the previously discussed phase II trials, the 2 FDA approved PARP inhibitors, olaparib and talazoparib, are included as category 1 preferred options for those with germline *BRCA1/2* mutations. The NCCN panel recommends assessing for germline *BRCA1/2* mutations in all patients with recurrent or metastatic breast cancer to identify candidates for PARP inhibitor therapy. Although olaparib and talazoparib are FDA indicated in HER2-negative disease, the NCCN panel supports use in any breast cancer subtype associated with germline *BRCA1/2* mutations.

Platinums

The phase III TNT trial compared docetaxel with carboplatin in the first-line setting in women ($n=376$) with triple-negative breast cancer. In the unselected population, carboplatin was not more active than docetaxel (ORR, 31.4% vs 34.0%; $P=.66$).¹¹⁵ Patients with a germline *BRCA1/2* mutation had a significantly better response to carboplatin than docetaxel (ORR, 68.0% vs 33.3%, absolute difference, 34.7%; $P=.03$).¹¹⁵ PFS was also improved with carboplatin treatment in patients with a germline *BRCA1/2* mutation (median PFS, 6.8 vs 4.4 months), no difference was found in OS. However, patients with somatic *BRCA1/2* mutation in the tumor DNA did not appear to have the same advantage.

For those with triple-negative recurrent or stage IV breast cancer and germline *BRCA1/2* mutations, the NCCN panel has included platinum agents (cisplatin and carboplatin) as preferred treatment options. It is unknown how PARP inhibitors compare with platinum agents in this setting.

Systemic Therapy for PD-L1–Positive, Triple-negative, Recurrent or Stage IV Disease

In a randomized trial (IMpassion 130), patients ($n=902$) with triple-negative breast cancer who had not received

treatment in the metastatic setting were randomized to the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab plus albumin-bound paclitaxel or placebo plus albumin-bound paclitaxel.¹¹⁶

All patients enrolled in the trial had to have completed previous chemotherapy (preoperative or adjuvant) at least 12 months before randomization and not received any chemotherapy in the metastatic setting. At a median follow-up of 12.9 months, there was statistically significant difference in PFS in those receiving atezolizumab plus albumin-bound paclitaxel than in the placebo plus albumin-bound paclitaxel (7.2 vs 5.5 months; HR for progression or death, 0.80; 95% CI, 0.69–0.92), and a nonsignificant trend toward improved OS (21.3 vs 17.6 months; HR for death, 0.84; 95% CI, 0.69–1.02).¹¹⁶ However, in a planned subset analysis of patients with PD-L1-expressing tumors, treatment with atezolizumab plus albumin-bound paclitaxel showed statistically significant improvement in PFS (7.5 vs 5 months; HR, 0.62; 95% CI, 0.49–0.78), and OS (25 vs 15.5 months; HR, 0.62; 95% CI, 0.45–0.86).¹¹⁶ Grade 3 or higher adverse events occurred in 48.7% receiving atezolizumab plus albumin-bound paclitaxel versus 42.2% receiving placebo plus albumin-bound paclitaxel. Grade 3 or 4 neuropathy was more frequently seen among those receiving atezolizumab (5.5% vs 2.7%). There were 3 treatment-related deaths among the patients who received atezolizumab, consistent with other studies of checkpoint inhibitors. Adverse events led to treatment discontinuation in 16% in the atezolizumab arm versus 8% in the control arm.¹¹⁶ PD-L1-positive expression in tumor-infiltrating immune cells of 1% or more has been associated with a better outcome with PD-L1 inhibitor treatment.¹¹⁷ A subsequent 18-month follow-up analysis confirmed PFS and OS benefits among those with PD-L1-expressing tumors.¹¹⁸ Atezolizumab plus albumin-bound paclitaxel is included as a preferred option for those with advanced triple-negative breast cancer with PD-L1 expression in $\geq 1\%$ tumor-infiltrating immune cells.

Systemic Chemotherapy for Recurrent or Stage IV Disease

Women with HR-negative tumors not localized to the bone or soft tissue only or that are associated with symptomatic visceral metastasis irrespective of HR- or HER-status, or that have HR-positive tumors that are refractory to endocrine therapy should receive systemic chemotherapy.

A variety of chemotherapy regimens are felt to be appropriate, as outlined in the treatment algorithm. Combination chemotherapy generally provides higher rates of objective response and longer time to progression, in comparison with single-agent chemotherapy. Combination chemotherapy is, however, associated with an increase in toxicity and is of little survival

benefit.^{119–123} Furthermore, administering single agents sequentially decreases the likelihood that dose reductions will be needed. Thus, the NCCN panel finds no compelling evidence that combination chemotherapy is superior to sequential single agents. Therefore, sequential monotherapy is preferred and combination therapy is useful in patients with rapid clinical progression or need for rapid symptom and/or disease control.

Usually the first-line regimens are given until progression or unacceptable toxicity. What is unacceptable toxicity and considering no further cytotoxic therapy should be decided together with the patient. Adverse effects may require dose reduction and cessation of chemotherapy prior to disease progression.

The NCCN panel recommends considering scalp cooling to reduce incidence of chemotherapy-induced alopecia for patients receiving chemotherapy. The data on efficacy of scalp cooling is mainly from the adjuvant setting and also show that results may be less effective with anthracycline-containing regimens.^{124–128}

A meta-analysis showed favorable impact on OS by prolonging treatment until disease progression.¹²⁹ In this analysis, data from 4 studies involving 666 patients indicated that median OS was increased by 23% (95% CI, 9%–38%; $P=.01$) in women receiving longer durations of chemotherapy versus a limited number of cycles.¹²⁹ In a systematic review, longer durations of chemotherapy demonstrated a marginal increase in OS (HR, 0.91; 95% CI, 0.84–0.99) and a significant improvement in PFS (HR, 0.66; 95% CI, 0.6–0.72), compared with shorter durations.¹²³

A more recent study of patients ($n=420$) with HER2-negative, advanced breast cancer showed that intermittent first-line treatment with paclitaxel plus bevacizumab was not inferior to continuous treatment. The median overall PFS for intermittent versus continuous was 7.4 months and 9.7 months, respectively (HR, 1.17; 95% CI, 0.88–1.57). Median OS was 17.5 months versus 20.9 months for intermittent versus continuous treatment, with a HR of 1.38 (95% CI, 1.00–1.91).¹³⁰

Determining the duration of chemotherapy in an individual patient typically depends on the efficacy and tolerability and shared decision-making between the treating physician and patient. Most patients will be candidates for multiple lines of systemic therapies for palliation. At each reassessment, clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.

Preferred Chemotherapy Regimens for Stage IV or Recurrent Metastatic Disease

The NCCN panel has classified the chemotherapy agents into 3 categories: “preferred,” “other recommended,”

and “useful in certain circumstances.” The treatment decision should be individualized and consider previous therapies, pre-existing comorbidities, nature of the disease, toxicity profiles, patient preferences, and in some cases access to agents.

Among preferred single agents, the NCCN panel has included taxanes (paclitaxel), anthracyclines (doxorubicin and liposomal doxorubicin), antimetabolites (capecitabine and gemcitabine), microtubule inhibitors (eribulin and vinorelbine), and platinum agents for patients with triple-negative tumors and germline *BRCA1/2* mutations.

Paclitaxel can be administered weekly (80 mg/m²)¹³¹ or every 3 weeks (175 mg/m²).⁸⁸ A meta-analysis of randomized controlled trials that compared weekly and every-3-week taxanes regimens in advanced breast cancer showed that compared with every-3-week treatment, weekly administration of paclitaxel resulted in an improvement in OS (HR, 0.78; 95% CI, 0.67–0.89).¹³²

Doxorubicin 60–75 mg/m² every 3 weeks or 20 mg/m² weekly has shown an ORR between 30% and 47%.^{133–136} Liposomal doxorubicin (50 mg/m² every 4 weeks) has been shown to have efficacy similar to doxorubicin (60 mg/m² every 3 weeks).¹³⁷ It has also been shown to have efficacy in the second-line setting for patients with metastatic breast cancer.¹³⁷ Compared with doxorubicin, liposomal doxorubicin has a less-frequent dosing schedule and decreased risk of cardiotoxicity (7% vs 26%; HR, 3.16; 95% CI, 1.58–6.31), decreased rate of nausea (37% vs 53%) and vomiting (19% vs 31%), lower rates of alopecia (20% vs 66%), and neutropenia (4% vs 10%).¹³⁷ However, compared with doxorubicin, it was associated with a higher rate of palmar-plantar erythrodysesthesia (48% vs 2%), stomatitis (22% vs 15%), and mucositis (23% vs 13%).¹³⁷

The benefit of capecitabine as a treatment option for patients with metastatic breast cancer has been demonstrated in multiple phase II trials. Results of one study of patients ($n=126$) treated with capecitabine showed ORR of 28%, median time to progression of 4.9 months and median OS of 15.2 months (95% CI, 13.5–19.6 months).¹³⁸ In another study, women ($n=95$) were randomized to receive capecitabine or cyclophosphamide, methotrexate, and fluorouracil (CMF).¹³⁹ Treatment with single agent capecitabine resulted in a higher ORR compared with CMF (30% vs 16%). The median time to progression and OS were similar in both groups.¹³⁹

Eribulin is a nontaxane microtubule inhibitor used for the treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. In a phase III trial, patients ($n=762$) with

metastatic breast cancer were randomized 2:1 to eribulin or treatment of physicians' choice. The OS was improved in women assigned to eribulin (median 13.1 months; 95% CI, 11.8–14.3) compared with those receiving other treatments (10.6 months; 9.3–12.5), a 19% statistically significant risk reduction (HR, 0.81, 95% CI, 0.66–0.99; $P=.041$).¹⁴⁰

A phase III trial compared eribulin with capecitabine in patients with metastatic breast cancer and showed that both treatments were similar with respect to OS and PFS.¹⁴¹ The median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR, 1.08; 95% CI, 0.93–1.25; $P=.30$) and the OS with eribulin versus capecitabine was 15.9 versus 14.5 months (HR, 0.88; 95% CI, 0.77–1.00).¹⁴¹

In addition to the previously noted, gemcitabine¹⁴² and vinorelbine are both active as single agents even in heavily pretreated patients with metastatic breast cancer.^{143–145} Among other recommended single agents, the NCCN panel has included taxanes (docetaxel,¹⁴⁶ albumin-bound paclitaxel^{147–149}), anthracyclines (epirubicin)¹⁵⁰, and ixabepilone.^{151–153} as other recommended regimens.

Ixabepilone as monotherapy has been evaluated in several phase II trials of women with metastatic breast cancer: in a first-line setting in patients previously treated with anthracycline chemotherapy¹⁵¹; in patients with taxane-resistant metastatic breast cancer¹⁵²; and in patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.¹⁵³ In the phase II trials, ORR, median duration of response, and median OS duration were 41.5% (95% CI, 29.4%–54.4%), 8.2 months (95% CI, 5.7–10.2 months), and 22.0 months (95% CI, 15.6–27.0 months) in the first-line setting¹⁵¹; 12% (95% CI, 4.7%–26.5%), 10.4 months, and 7.9 months for the taxane-resistant patients¹⁵²; and 11.5% (95% CI, 6.3%–18.9%), 5.7 months, and 8.6 months for the patients previously treated with an anthracycline, a taxane, and capecitabine.¹⁵³ In the study by Perez et al,¹⁵³ grade 3/4 treatment-related toxicities included peripheral sensory neuropathy (14%) and neutropenia (54%).

The NCCN panel had included combination chemotherapy regimens as useful in certain circumstances. The combination regimen options include doxorubicin/cyclophosphamide (AC)^{154,155}; epirubicin/cyclophosphamide (EC)¹⁵⁶; docetaxel and capecitabine¹²¹; gemcitabine and paclitaxel (GT)¹⁵⁷; cyclophosphamide/methotrexate/fluorouracil (CMF)¹⁵⁸; gemcitabine/carboplatin^{159–161}; carboplatin with paclitaxel or albumin-bound paclitaxel^{162–164}; and paclitaxel/bevacizumab.^{165–167}

For the doublet regimens that are included, randomized phase III trials have shown that the ORR with first-line AC treatment ranges from 47% to 54% and OS is around 20 months.^{154,155} For first-line EC, the ORR

reported from a phase III trial is 7.1 months and OS was 14 months.¹⁵⁶ For first-line capecitabine/docetaxel, a phase III trial reported an ORR of 53% and time to progression of 11 months.¹⁶⁸ In the second-line setting, another phase III trial compared the efficacy and tolerability of capecitabine/docetaxel therapy in anthracycline-pretreated patients and showed significantly superior efficacy in time to disease progression (HR, 0.652; 95% CI, 0.545–0.780; $P=.0001$; median, 6.1 vs 4.2 months), OS (HR, 0.775; 95% CI, 0.634–0.947; $P=.0126$; median, 14.5 vs 11.5 months), and ORR (42% v 30%, $P=.006$) compared with single-agent docetaxel.¹²¹

Combination chemotherapy regimens containing a platinum agent or a taxane have been shown to be efficacious in patients with metastatic triple-negative breast cancer. A randomized phase II study compared the addition of iniparib to gemcitabine/carboplatin versus gemcitabine/carboplatin in patients with triple-negative breast cancer who had received no more than 2 prior chemotherapies. ORR was similar in both groups: 30.2% (95% CI, 24.6–35.8) with gemcitabine/carboplatin,¹⁵⁹ and the median OS was 11.1 months with gemcitabine/carboplatin (HR, 0.88; 95% CI, 0.69–1.12).¹⁵⁹

Several phase II studies have evaluated the efficacy of paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer and found the combination to be an effective therapeutic option in this setting.^{163,164} The randomized trial, tnAcity, evaluated the efficacy and safety of first-line albumin-bound paclitaxel plus carboplatin, albumin-bound paclitaxel plus gemcitabine, and gemcitabine plus carboplatin in patients with metastatic triple-negative breast cancer.¹⁶² The results of this trial reported that median PFS was significantly longer with albumin-bound paclitaxel plus carboplatin versus albumin-bound paclitaxel/gemcitabine (8.3 vs 5.5 months; HR, 0.59; 95% CI, 0.38–0.92; $P=.02$) or gemcitabine/carboplatin (8.3 vs 6.0 months; HR, 0.58; 95% CI, 0.37–0.90; $P=.02$). The median OS was also longer with albumin-bound paclitaxel plus carboplatin versus albumin-bound paclitaxel/gemcitabine (16.8 vs 12.1 months; HR, 0.73; 95% CI, 0.47–1.13; $P=.16$) or gemcitabine/carboplatin (16.8 vs 12.6 months; HR, 0.80; 95% CI, 0.52–1.22; $P=.29$). The ORRs were 73%, 39%, and 44%, respectively.¹⁶²

A series of trials have sought to define the role for bevacizumab in the treatment of metastatic breast cancer. The E2100 trial randomized 722 women with recurrent or metastatic breast cancer to first-line chemotherapy with paclitaxel with or without bevacizumab.¹⁶⁵ This trial documented superior PFS (11.8 vs 5.9 months; HR, 0.60; $P<.001$) favoring bevacizumab plus paclitaxel compared with paclitaxel alone. A similar trial enrolled 736 patients who were randomized to treatment with docetaxel and

bevacizumab or docetaxel and placebo.¹⁶⁹ This trial also documented increased PFS in the arm containing bevacizumab (10.1 vs 8.2 months with docetaxel alone; HR 0.77; $P=.006$). An additional trial, RIBBON-1, combined bevacizumab with capecitabine, with a taxane (docetaxel, nab-paclitaxel), with anthracyclines (FEC, CAF, AC, or EC), or with the same chemotherapy alone. Results of this trial show a statistically significant increase in PFS with bevacizumab and capecitabine (8.6 vs 5.7 months; HR, 0.69; $P<.001$) and taxane- or anthracycline- (9.2 months vs 8.0 months; HR, 0.64; $P<.001$) containing arms.^{166,167} In a subset analysis of the phase III CALGB 40502 trial, for patients ($n=201$) with metastatic triple-negative breast cancer, first-line albumin-bound paclitaxel in combination with bevacizumab resulted in a median PFS of 7.4 months.¹⁷⁰

The NCCN panel notes that albumin-bound paclitaxel may be substituted for paclitaxel or docetaxel due to medical necessity (ie, hypersensitivity reaction). If substituted for weekly paclitaxel or docetaxel, then the weekly dose of nab-paclitaxel should not exceed 125 mg/m².

The data from the previously mentioned randomized trials document that the addition of bevacizumab to first- or second-line chemotherapy agents modestly improves time to progression and response rates. The time-to-progression impact may vary among cytotoxic agents and appears greatest with bevacizumab in combination with weekly paclitaxel. None of these studies demonstrates an increase in OS or QOL when analyzed alone or in a meta-analysis of the trials.¹⁷¹ Therefore, the NCCN panel has included bevacizumab in combination with paclitaxel as an option useful in only select circumstances.

The only triplet regimen listed as an option in the metastatic setting is CMF. This regimen was compared in the first-line setting with capecitabine monotherapy, and results show similar ORR and PFS.¹⁵⁸ However, CMF

resulted in a shorter OS (median, 22 vs 18 months; HR, 0.72; 95% CI, 0.55–0.94) compared with capecitabine.

Additional Targeted Therapies for Stage IV Disease Useful in Certain Circumstances

Neurotrophic tropomyosin receptor kinase (*NTRK*) gene fusions are seen in a few rare types of cancer, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma and also infrequently in some common cancers, such as melanoma, glioma, and carcinomas of the thyroid, lung, and colon.¹⁷² *NTRK* fusions are identified by fluorescence in situ hybridization, next generation sequencing, or polymerase chain reaction. Larotrectinib^{173–175} and entrectinib^{175,176} are 2 *NTRK*-inhibitors that are FDA approved for the treatment of solid tumors that have an *NTRK* gene fusion without a known acquired resistance mutation and have no satisfactory alternative treatments or that have progressed following treatment. If a patient with recurrent or stage IV breast cancer presents with a tumor with an *NTRK* fusion, treatment with an *NTRK* inhibitor is an option if no satisfactory alternative treatment exists or that have progressed following treatment.

Pembrolizumab is FDA approved for the treatment of patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options.^{177–179} Pembrolizumab has demonstrated anti-tumor activity in heavily pretreated patients with metastatic breast cancer and high tumor mutation burden (≥ 9 mutations/megabase) determined by commercially available tests.¹⁸⁰ If patient with recurrent or stage IV breast cancer has a tumor with microsatellite instability-high/mismatch repair deficient mutation, whose disease has progressed after prior treatments and no satisfactory alternative treatment options, treatment with pembrolizumab is an option.

References

- Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. *Cancer* 1994; 74(1, Suppl):416–423.
- Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. *Ann Surg Oncol* 2006;13:776–782.
- Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? *Surgery* 2002;132:620–626., discussion 626–627.
- Rao R, Feng L, Kuerer HM, et al. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. *Ann Surg Oncol* 2008; 15:1696–1702.
- Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. *J Clin Oncol* 2006;24:2743–2749.
- Morrow M, Goldstein L. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted? *J Clin Oncol* 2006;24:2694–2696.
- Olson JA, Jr., Marcom PK. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. *Ann Surg* 2008;247:739–740.
- Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. *Lancet Oncol* 2015;16: 1380–1388.
- King TA, Lyman JP, Gonen M, et al. Prognostic impact of 21-gene recurrence score in patients with stage IV breast cancer: TBCRC 013. *J Clin Oncol* 2016;34:2359–2365.
- King TA, Lyman J, Gonen M, et al. A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). *J Clin Oncol* 2016; 34(15_suppl):1006–1006.
- Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. *Ann Surg Oncol* 2018;25: 3141–3149.

12. Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer. *Oncology (Williston Park)* 2008;22:614–623, discussion 623, 627–629.
13. Woo S-B, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. *Ann Intern Med* 2006;144:753–761.
14. Diel IJ, Body JJ, Lichinitser MR, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. *Eur J Cancer* 2004;40:1704–1712.
15. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. *J Clin Oncol* 1998;16:2038–2044.
16. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. *N Engl J Med* 1996;335:1785–1791.
17. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. *Cancer* 2000;88:1082–1090.
18. McLachlan SA, Cameron D, Murray R, et al. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. *Clin Drug Investig* 2006;26:43–48.
19. Pecherstorfer M, Rivkin S, Body J-J, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. *Clin Drug Investig* 2006;26:315–322.
20. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. *Cancer* 2004;100:36–43.
21. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. *J Clin Oncol* 1999;17:846–854.
22. Amadori D, Aglietta M, Alessi B, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. *Lancet Oncol* 2013;14:663–670.
23. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. *JAMA* 2017;317:48–58.
24. Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. *JAMA Oncol* 2017;3:906–912.
25. Hortobagyi GN, Lipton A, Chew HK, et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. *ASCO Meeting Abstracts* 2014;32:LBA9500.
26. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. *Cancer* 2003;98:1735–1744.
27. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol* 2010;28:5132–5139.
28. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med* 2016;375:1925–1936.
29. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol* 2018;29:1541–1547.
30. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol* 2017;35:3638–3646.
31. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. *Lancet Oncol* 2018;19:904–915.
32. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. *N Engl J Med* 2019;381:307–316.
33. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. *J Clin Oncol* 2009;27:4530–4535.
34. Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. *Breast Cancer Res Treat* 2012;136:503–511.
35. Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Overall survival analysis from the phase II FIRST study. *J Clin Oncol* 2015;33:3781–3787.
36. Di Leo A, Jerusalem G, Petruzella L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. *J Clin Oncol* 2010;28:4594–4600.
37. Di Leo A, Jerusalem G, Petruzella L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. *J Natl Cancer Inst* 2014;106:djt337.
38. Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. *Lancet* 2016;388:2997–3005.
39. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. *J Clin Oncol* 2018;36:2465–2472.
40. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. *N Engl J Med* 2020;382:514–524.
41. Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. *J Clin Oncol* 2012;30:1919–1925.
42. Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. *Lancet Oncol* 2013;14:989–998.
43. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. *N Engl J Med* 2012;367:435–444.
44. Mehta RS, Barlow WE, Albain KS, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. *N Engl J Med* 2019;380:1226–1234.
45. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. *J Clin Oncol* 2001;19:3357–3366.
46. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. *Cancer* 1998;83:1142–1152.
47. Campos SM, Guastalla JP, Subar M, et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. *Clin Breast Cancer* 2009;9:39–44.
48. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. *J Clin Oncol* 1991;9:1283–1297.
49. Bonnetterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. *J Clin Oncol* 2000;18:3748–3757.
50. Nabholz JM, Buzdar A, Pollak M, et al. Arimidex Study Group. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. *J Clin Oncol* 2000;18:3758–3767.
51. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European

- Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. *J Clin Oncol* 2008;26:4883–4890.
52. Vergote I, Bonnetterre J, Thürlimann B, et al. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. *Eur J Cancer* 2000;36(Suppl 4): S84–S85.
 53. Mauri D, Pavlidis N, Polyzos NP, et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. *J Natl Cancer Inst* 2006;98: 1285–1291.
 54. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2015;373:209–219.
 55. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol* 2016;17:425–439.
 56. Sledge GW, Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol* 2017;35:2875–2884.
 57. Sledge GW, Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial [published online September 29, 2019]. *JAMA Oncol*, doi: 10.1001/jamaoncol.2019.4782
 58. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. *J Clin Oncol* 2002;20:3396–3403.
 59. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. *J Clin Oncol* 2002;20:3386–3395.
 60. Ingle JN, Suman VJ, Rowland KM, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. *J Clin Oncol* 2006;24:1052–1056.
 61. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFFECT. *J Clin Oncol* 2008;26:1664–1670.
 62. André F, Ciruelos E, Rubovszky G, et al. SOLAR-1 Study Group. Alpelisib for *PIK3CA*-mutated, hormone receptor-positive advanced breast cancer. *N Engl J Med* 2019;380:1929–1940.
 63. Bachelot T, Bourcier C, Cropet C, et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI) [abstract]. *Cancer Res* 2010;70(24 Supplement): Abstract:S1–6
 64. Chow L, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. *Breast Cancer Res Treat* 2006; 100(Suppl 1):6091.
 65. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. *Adv Ther* 2013;30:870–884.
 66. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012; 366:520–529.
 67. Pritchard KI, Burris HA, 3rd, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. *Clin Breast Cancer* 2013;13:421–432 e8.
 68. Dixon JM, Renshaw L, Langridge C, et al. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. *Breast Cancer Res Treat* 2011;125:741–749.
 69. Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. *Eur J Cancer* 2003; 39:2318–2327.
 70. Thürlimann B, Robertson JF, Nabholz JM, et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. *Eur J Cancer* 2003;39:2310–2317.
 71. Abrams J, Aisner J, Cirincione C, et al. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. *J Clin Oncol* 1999;17:64–73.
 72. Willemse PH, van der Ploeg E, Sleijfer DT, et al. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. *Eur J Cancer* 1990;26: 337–343.
 73. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. *J Clin Oncol* 1996;14:2000–2011.
 74. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. *JAMA* 2009;302: 774–780.
 75. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. *Clin Cancer Res* 2017;23:5218–5224.
 76. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med* 2012;366:109–119.
 77. Swain S, Kim S-B, Cortes J, et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC) [abstract]. *Cancer Res* 2012;72(Suppl):P5-18-26.
 78. Ewer M, Baselga J, Clark E, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study [abstract]. *J Clin Oncol* 2012; 30(Suppl):Abstract 533.
 79. Cortés J, Baselga J, Im Y, et al. Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer [abstract]. *J Clin Oncol* 2012;30(Suppl): Abstract 598.
 80. Bachelot T, Ciruelos E, Schneeweiss A, et al. PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). *Ann Oncol* 2019;30:766–773.
 81. Datko F, D'Andrea G, Dickler M, et al. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer [abstract]. *Cancer Res* 2012; 72(Suppl):Abstract P5-18-20.
 82. Paclitaxel, trastuzumab, and pertuzumab in the treatment of metastatic HER2-positive breast cancer (Clinical Trial ID: NCT01276041). Available at: <http://clinicaltrials.gov/show/NCT01276041>. Accessed March 9, 2020.
 83. Perez E, Lopez-Vega J, Mastro L, et al. A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET) [abstract]. *J Clin Oncol* 2012;30(Suppl):Abstract TPS653.
 84. Ellis PA, Barrios CH, Eiermann W, et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study [abstract]. *J Clin Oncol* 2015;33(Suppl):507.
 85. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;344:783–792.
 86. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. *Cancer* 2007; 110:965–972.
 87. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. *J Clin Oncol* 2006;24:2786–2792.
 88. Seidman AD, Berry D, Cirincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. *J Clin Oncol* 2008;26: 1642–1649.

89. Schaller G, Bangemann N, Weber J, et al. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer [abstract]. *J Clin Oncol* 2005; 23(Suppl):Abstract 717.
90. Yamamoto D, Iwase S, Kitamura K, et al. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. *Cancer Chemother Pharmacol* 2008;61:509–514.
91. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. *J Clin Oncol* 2002;20:1215–1221.
92. Bartsch R, Wenzel C, Altörjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. *J Clin Oncol* 2007;25:3853–3858.
93. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. *J Clin Oncol* 2009;27:1999–2006.
94. Von Minckwitz G, Zielinski C, Maerteense E, et al. Capecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) [abstract]. *J Clin Oncol* 2008;26(Suppl): Abstract 1025.
95. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. *J Clin Oncol* 2010;28:1138–1144.
96. Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 2012;30:1594–1600.
97. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 2012;367:1783–1791.
98. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med* 2020;382:610–621.
99. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med* 2006;355:2733–2743.
100. Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. *Oncologist* 2010;15:924–934.
101. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. *J Clin Oncol* 2010;28:1124–1130.
102. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. *J Clin Oncol* 2012;30:2585–2592.
103. Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. *J Clin Oncol* 2019;37:1081–1089.
104. Saura C, Oliveira M, Feng Y-H, et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. *J Clin Oncol* 2019;37(suppl):1002–1002.
105. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. *J Clin Oncol* 2009;27:5529–5537.
106. Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. *Breast* 2012;21:27–33.
107. Johnston S, Pippen J Jr, Pivov X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. *J Clin Oncol* 2009; 27:5538–5546.
108. Rimawi M, Ferrero JM, de la Haba-Rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): A randomized, open-label phase II trial. *J Clin Oncol* 2018; 36:2826–2835.
109. Gradishar WJ, Hegg R. Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE. *J Clin Oncol* 2017;35(suppl):1004–1004.
110. Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. *Cancer Res* 2006;66:8297–8308.
111. Kurian AW, Gong GD, John EM, et al. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. *Cancer Epidemiol Biomarkers Prev* 2009;18:1084–1091.
112. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med* 2017;377: 523–533.
113. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. *Ann Oncol* 2019;30: 558–566.
114. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med* 2018;379: 753–763.
115. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. *Nat Med* 2018;24:628–637.
116. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med* 2018;379: 2108–2121.
117. Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. *JAMA Oncol* 2019;5: 74–82.
118. Schmid P, Adams S, Rugo HS, et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). *J Clin Oncol* 2019;37(Suppl):1003–1003.
119. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival [abstract]. *J Clin Oncol* 2004;22(Suppl):510.
120. Carrick S, Parker S, Wilcken N, et al. Single agent versus combination chemotherapy for metastatic breast cancer. *Cochrane Database Syst Rev* 2005;2:CD003372.
121. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. *J Clin Oncol* 2002;20:2812–2823.
122. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an intergroup trial (E1193). *J Clin Oncol* 2003;21:588–592.
123. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. *J Clin Oncol* 2011;29:2144–2149.
124. Giarratano T, Frezzini S, Zanocco M, et al. Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study [published online December 14, 2019]. *Breast J*, doi: 10.1111/tbj.13711
125. Kruse M, Abraham J. Management of chemotherapy-induced alopecia with scalp cooling. *J Oncol Pract* 2018;14:149–154.
126. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. *JAMA* 2017;317:596–605.
127. Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. *JAMA* 2017;317:606–614.
128. Rugo HS, Melin SA, Voigt J. Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases:

- systematic review and meta-analysis. *Breast Cancer Res Treat* 2017;163:199–205.
129. Stockler MR, Wilcken NJC, Coates AS. Chemotherapy for advanced breast cancer – how long should it continue? *Breast Cancer Res Treat* 2003;81(Suppl 1):49–52.
 130. Claessens AKM, Bos MEMM, Lopez-Yurda M, et al. Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). *Breast Cancer Res Treat* 2018;172:413–423.
 131. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. *J Clin Oncol* 2001;19:4216–4223.
 132. Mauri D, Kamposioras K, Tsali L, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. *Cancer Treat Rev* 2010;36:69–74.
 133. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. *J Clin Oncol* 1999;17:2341–2354.
 134. Gasparini G, Dal Fior S, Panizzoni GA, et al. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. *Am J Clin Oncol* 1991;14:38–44.
 135. Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. *J Clin Oncol* 2000;18:2385–2394.
 136. Andersson M, Daugaard S, von der Maase H, et al. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study. *Cancer Treat Rep* 1986;70:1181–1186.
 137. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann Oncol* 2004;15:440–449.
 138. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. *Eur J Cancer* 2004;40:536–542.
 139. O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. *Ann Oncol* 2001;12:1247–1254.
 140. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet* 2011;377:914–923.
 141. Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol* 2015;33:594–601.
 142. Vernieri C, Prisciandaro M, Milano M, et al. Single-agent gemcitabine vs. carboplatin-gemcitabine in advanced breast cancer: a retrospective comparison of efficacy and safety profiles. *Clin Breast Cancer* 2019;19:e306–e318.
 143. Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. *J Clin Oncol* 1995;13:2567–2574.
 144. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. *J Clin Oncol* 1993;11:1245–1252.
 145. Martín M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. *Lancet Oncol* 2007;8:219–225.
 146. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. *J Clin Oncol* 2005;23:5542–5551.
 147. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. *J Clin Oncol* 2005;23:6019–6026.
 148. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* 2005;23:7794–7803.
 149. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. *J Clin Oncol* 2009;27:3611–3619.
 150. Bastholt L, Dalmark M, Gjedde SB, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. *J Clin Oncol* 1996;14:1146–1155.
 151. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. *J Clin Oncol* 2007;25:3415–3420.
 152. Thomas E, Tabernero J, Fomier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. *J Clin Oncol* 2007;25:3399–3406.
 153. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. *J Clin Oncol* 2007;25:3407–3414.
 154. Nabholz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. *J Clin Oncol* 2003;21:968–975.
 155. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. *J Clin Oncol* 2002;20:3114–3121.
 156. Langley RE, Carmichael J, Jones AL, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. *J Clin Oncol* 2005;23:8322–8330.
 157. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. *J Clin Oncol* 2008;26:3950–3957.
 158. Stockler MR, Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. *J Clin Oncol* 2011;29:4498–4504.
 159. O'Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. *J Clin Oncol* 2014;32:3840–3847.
 160. Yardley DA, Brufsky A, Coleman RE, et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. *Trials* 2015;16:575.
 161. Nelli F, Moscetti L, Natoli G, et al. Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. *Int J Clin Oncol* 2013;18:343–349.
 162. Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. *Ann Oncol* 2018;29:1763–1770.
 163. Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. *Cancer* 2000;88:124–131.
 164. Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. *Ann Oncol* 2004;15:1517–1526.
 165. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007;357:2666–2676.
 166. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract]. *J Clin Oncol* 2009;27(Suppl):1005.
 167. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor

- receptor 2-negative, locally recurrent or metastatic breast cancer. *J Clin Oncol* 2011;29:1252–1260.
168. Mavroudis D, Papakotoulas P, Ardavanis A, et al. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. *Ann Oncol* 2010;21:48–54.
 169. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol* 2010;28:3239–3247.
 170. Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). *J Clin Oncol* 2015;33:2361–2369.
 171. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment of patients with metastatic breast cancer (MBC) [abstract]. *J Clin Oncol* 2010;28(Suppl):1005.
 172. Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. *Nat Commun* 2014;5:4846.
 173. Dilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med* 2018;378:731–739.
 174. Meric-Bernstam F, Shukla N, Peled N, et al. Abstract P6-20-02: Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers. *Cancer Res* 2019;79(Suppl):P6-20-02.
 175. Dilon A. TRK inhibitors in TRK fusion-positive cancers. *Ann Oncol* 2019;30(Suppl 8):viii23–viii30.
 176. Demetri GD, Paz-Ares L, Farago AF, et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. *Ann Oncol* 2018;29(Suppl 8):viii713.
 177. Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. *Ann Oncol* 2019;30:405–411.
 178. Phan K, Charif M. Pembrolizumab for PD-L1-positive breast cancer refractory to chemotherapy [published online. *Am J Ther*, doi: 10.1097/MJT.0000000000001015
 179. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. *J Clin Oncol* 2016;34:2460–2467.
 180. Alva AS, Mangat PK, Garrett-Mayer E, et al. Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. *J Clin Oncol* 2019;37(suppl): 1014–1014.

Individual Disclosures for the NCCN Breast Cancer Panel

Panel Member	Clinical Research Support/Data Safety Monitoring Board	Scientific Advisory Boards, Consultant, or Expert Witness	Promotional Advisory Boards, Consultant, or Speakers Bureau	Specialties
Jame Abraham, MD	Daiichi-Sankyo Co.; Pfizer Inc.; and Seattle Genetics, Inc.	None	None	Hematology/Hematology Oncology, and Medical Oncology
Rebecca Aft, MD, PhD	None	None	None	Surgery/Surgical Oncology
Doreen Agnese, MD	None	None	None	Surgery/Surgical Oncology
Kimberly H. Allison, MD	None	None	None	Pathology
Benjamin O. Anderson, MD	None	UE LifeSciences, Inc.	None	Surgery/Surgical Oncology
Sarah L. Blair, MD*	None	Kairos Ventures	None	Surgery/Surgical Oncology
Harold J. Burstein, MD, PhD	None	None	None	Medical Oncology
Chau Dang, MD	Genentech, Inc.; PUMA; and Roche Laboratories, Inc.	Daiichi-Sankyo Co., and PUMA	None	Medical Oncology
Anthony D. Elias, MD	None	SIX1 Therapeutics	None	Medical Oncology
Sharon H. Giordano, MD, MPH	None	None	None	Medical Oncology
Matthew P. Goetz, MD	Eli Lilly and Company; Pfizer Inc.; and Sermonix Pharmaceuticals	Eli Lilly and Company; Novartis Pharmaceuticals Corporation; and Sermonix Pharmaceuticals	None	Hematology/Hematology Oncology, and Medical Oncology
Lori J. Goldstein, MD	Daiichi-Sankyo Co.	Eisai Inc.; Genentech, Inc.; Merck & Co., Inc.; and Mylan	None	Medical Oncology
William J. Gradishar, MD	Genentech, Inc., and Seattle Genetics, Inc.	Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Genentech, Inc.; Merck & Co., Inc.; and Pfizer Inc.	None	Hematology/Hematology Oncology, and Medical Oncology
Steven J. Isakoff, MD, PhD	AbbVie, Inc.; AstraZeneca Pharmaceuticals LP; Genentech, Inc.; Merck & Co., Inc.; OncoPep, Inc.; Pharmamar Inc.	Mylan, and Puma	None	Medical Oncology
Jairam Krishnamurthy, MD	None	None	AbbVie, Inc., and AstraZeneca Pharmaceuticals LP	Medical Oncology
Janice Lyons, MD	None	None	None	Radiation Oncology/Radiotherapy
P. Kelly Marcom, MD	AbbVie, Inc.; Celldex Therapeutics; Genentech, Inc.; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation	AbbVie, Inc.; Celtrion; Immunomedics, Inc.; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation	None	Medical Oncology
Jennifer Matro, MD	None	None	None	Medical Oncology
Ingrid A. Mayer, MD	AbbVie, Inc.; AstraZeneca Pharmaceuticals LP; Genentech, Inc.; Immunomedics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Polyphor; and PUMA	AbbVie, Inc.; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Immunomedics, Inc.; MacroGenics, Inc. Novartis Pharmaceuticals Corporation; Pfizer Inc.; PUMA; and Seattle Genetics, Inc.	None	Medical Oncology
Meena S. Moran, MD	None	None	None	Radiation Oncology/Radiotherapy
Joanne Mortimer, MD	None	None	Karyopharm Therapeutics	Medical Oncology
Ruth M. O'Regan, MD	Eisai Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Seattle Genetics, Inc.; and TTC Pharmaceuticals	Biotheranostics, Inc.; Eli Lilly and Company; Genentech, Inc.; Genomic Health, Inc.; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and PUMA	None	Medical Oncology
Sameer A. Patel, MD	None	None	None	Reconstructive Surgery
Lori J. Pierce, MD	None	None	None	Radiation Oncology/Radiotherapy
Hope S. Rugo, MD	Amgen Inc.; AstraZeneca Pharmaceuticals LP; Daiichi-Sankyo Co.; Eisai Inc.; Genentech, Inc.; Immunomedics, Inc.; Eli Lilly and Company; MacroGenics, Inc.; Merck & Co., Inc.; Mylan; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Odonate Therapeutics; Pfizer Inc.; Puma; and Seattle Genetics, Inc.	Celtrion, and Ionis Pharmaceuticals, Inc.	None	Medical Oncology
Amy Sitapati, MD	None	None	Epic Vendor, Safety Net Institute	Internal Medicine
Karen Lisa Smith, MD, MPH*	Pfizer Inc.	None	None	Medical Oncology
Mary Lou Smith, JD, MBA	None	None	Novartis Pharmaceuticals Corporation, and Pfizer Inc.	Patient Advocacy
Hatem Soliman, MD	None	AstraZeneca Pharmaceuticals LP; Celgene Corporation; Eisai Inc.; Novartis Pharmaceuticals Corporation; and PUMA	None	Medical Oncology
Erica M. Stringer-Reasor, MD	AbbVie, Inc.; GlaxoSmithKline; Pfizer Inc.; Seattle Genetics, Inc.; and TESARO, Inc.	Eli Lilly and Company, and Mylan	Eli Lilly and Company	Medical Oncology, and Hematology/Hematology Oncology
Melinda L. Telli, MD	Bayer HealthCare; Biothera; EMD Serono, Inc.; G1 Therapeutics; Genentech, Inc.; Immunomedics, Inc.; Merck & Co., Inc.; OncoSec Medical; Pfizer Inc.; PharmaMar, Inc.; TESARO, Inc.; and Vertex Pharmaceuticals Incorporated	AbbVie, Inc.; Aduro Biotech, Inc.; Celgene Corporation; Daiichi-Sankyo Co.; G1 Therapeutics; Genentech, Inc.; Eli Lilly and Company; Merck & Co., Inc.; and Pfizer Inc.	None	Medical Oncology, and Internal Medicine
John H. Ward, MD	None	None	None	Hematology/Hematology Oncology, and Medical Oncology
Jessica S. Young, MD	None	None	None	Surgery/Surgical Oncology

The NCCN Guidelines Staff have no conflicts to disclose.

*The following individuals have disclosed that they have an employment/governing board, patent, equity, or royalty:

Karen Lisa Smith, MD, MPH: Abbott Laboratories, and AbbVie, Inc.
 Sarah Blair, MD: Viewpoint Medical